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If this is a man. 
You who live safe 
In your warm houses 
You who find, returning in the evening 
Hot food and friendly faces: 
Consider if this is a man, 
Who works in the mud 
Who does not know peace 
Who fights for a scrap of bread 
Who dies because of a yes or no. 
Consider if this is a woman, 
Without hair and without name 
With no more strength to remember, 
Her eyes empty and her womb cold 
Like a frog in winter. 
Meditate that this came about: 
I commend these words to you. 
Carve them in your hearts 
At home, in the street, 
Going to bed, r i s i n g ~ ~
Or may your house fall apart, 
May illness impede you, 
May your children turn their faces from you. 
Primo Levi 1919-1987. 
ABSTRACT 
The aim of this work was to enhance the immune 
responses to ovalbumin (OVA) following its oral 
administration, by the association of the protein with 
colloidal carriers, which may protect the protein from 
degradation in the gastrointestinal tract and/or 
facilitate its uptake across the intestine. 
An enzyme linked immunosorbent assay (ELISA) was 
established for the determination of rat anti-OVA 
antibodies and an immunisation protocol was established 
to induce a statistically significant salivary antibody 
response to OVA in the rat. A radioimmunoassay for the 
determination of rat anti-OVA antibodies was also 
established, to confirm the ELISA results. Methods were 
established to determine the extent of incorporation or 
adsorption of OVA into or onto the colloidal carrier 
formulations. 
OVA was incorporated into liposomes and 
polyacrylamide microparticles, and adsorbed to poly 
2-butylcyanoacrylate particles, and gastrically 
intubated into separate groups of experimental rats. 
The primary and memory immune responses, both sera and 
saliva, were compared for each formulation with 
suitable control and blank groups. 
All colloidal carriers induced enhanced immune 
responses to OVA following oral administration in the 
rat, when compared with the respective control group 
responses. However, the enhancement for the liposomal 
group was not statistically significant when assessed 
in an Unpaired Student 't' test. 
The effect of particle size on the immune responses 
was assessed by the oral administration of lOOnm and 
3pm poly 2-butylcyanoacrylate particles with adsorbed 
OVA. 
An electron microscopy study was undertaken with 
gold labelled poly 2-butylcyanoacrylate particles in an 
attempt to demonstrate the uptake of particles by 
M-cells overlying the Peyers' patches in the rat 
intestine. 
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INTRODUCTION 
Progress in the field of biotechnology has renewed 
interest in the oral delivery of macromolecules. 
However, whilst small quantities of proteins and other 
macromolecules may be absorbed from the 
gastrointestinal tract intact (1-5), enzymatic 
degradation and poor absorption have limited the 
delivery of therapeutically active molecules such as 
insulin and heparin. Several mechanisms, both specific 
and non-specific, exist in the gut by which these 
materials pass from the lumenal surface to the systemic 
circulation. Future developments in the oral delivery 
of proteins is likely to depend on the exploitation of 
these normal physiological processes. However, the 
uptake of macromolecules is normally associated with 
lysosomal degradation which markedly reduces the amount 
of intact macromolecule reaching the circulation. 
Uptake of macromolecules by M-cells, which are 
specialised cells overlying the lymphoid follicles of 
the gastrointestinal tract and are involved in antigen 
uptake, does not appear to involve extensive 
degradation. However, the primary function of the 
M-cell is to provide the immune system with samples of 
gut antigen in order to stimulate the body's defence 
mechanisms against future absorption of the antigen. 
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Although the response of the immune system to absorbed 
antigen will limit the oral delivery of proteins, this 
may provide an attractive alternative to parenteral 
immunisation. The oral administration of antigens may 
prove to be a highly efficient method of producing 
secretory IgA at all mucosal sites and may be of great 
benefit in immunisation protocols which call for IgA 
antibody production. 
This project is concerned with investigating the 
immune responses, both serum and secretory, to a model 
protein administered orally. The protein was 
incorporated into, or adsorbed onto, colloidal carriers 
which were designed to confer protection of the protein 
against enzymatic destruction in the gastrointestinal 
tract (g.i.t.) and/or to facilitate uptake of the 
protein by M-cells. The overall aim was to enhance the 
immune responses induced by the protein, particularly 
the secretory immune response. If successful, this 
research effort may lead to applications in the 
development of effective oral vaccines against a number 
of organisms. 
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1.1. Evidence of intestinal absorption of proteins and 
macromolecules. 
During the perinatal period, proteins and 
macromolecules can readily penetrate the immature 
gastrointestinal mucosa. It had been assumed that this 
process ceases with maturation of the epithelial cells. 
However, increasing clinical and experimental evidence 
has shown that small amounts of antigenically active 
proteins and macromolecules can penetrate the adult 
intestinal epithelium (1-5). 
The clinical consequences of the exposure of the 
intestine to proteins are either the induction of an 
immune response or the loss of systemic reactivity to 
parenterally administered antigen (systemic tolerance). 
As early as 1935, Wilson and Walzer (6) demonstrated 
the presence of serum antibodies to proteins ingested 
in physiological quantities. This suggests that 
undigested protein can be absorbed and distributed 
throughout the body. Similarly 15-30% of normal adults 
have been shown to develop milk antibodies after 
ingestion of a small amount of milk proteins (7). An 
increase in the permeability of the gut to 
macromolecules is associated with certain intestinal 
disease states, and it is possible that the associated 
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rise in antigen absorption may account for some of the 
extra-intestinal symptoms of these conditions (8,9). 
Experimental investigations have clearly demonstrated 
that proteins and macromolecules can be absorbed intact 
from the gut. Warshaw et al (1) infused the enzyme 
horse radish peroxidase (HRP) through an indwelling 
catheter into the j e j ~ n u m m of rats and found that small 
amounts of protein tracer were consistently transmitted 
across the intestinal mucosa. Maximal portal blood 
concentrations ranged from 17.2 to 113.4 nglml after 
administration of a dose of 23mg/kg, and a maximum of 
0.153% of the administered dose was absorbed. Cornel et 
ale (10) reported the absorption of similar 
concentrations of HRP after intralumenal injection into 
ligated segments of jejenum and ileum in rats. 
Histological examination of the tissue showed HRP 
adsorbed to the apical surface membranes, within 
membrane bound cytoplasmic canalicular, vesicular and 
vacuolar structures, in the intercellular spaces 
between absorptive cells, traversing the basement 
membrane and within the spaces of the lamina propria. 
Comparison of the absorption of bovine serum albumin 
(BSA), HRP, elastase and chymotrypsin following 
infusion into rat duodenum, showed that 100 to 1000 
times more BSA than HRP was absorbed and that elastase 
and chymotrypsin were absorbed in quantities 
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intermediate between BSA and HRP (3). The reasons why 
there are such differences in the absorption of various 
proteins is not known, but it is likely that absorption 
depends on characteristics such as molecular weight, 
charge, configuration and structure. Bernstein and 
Ovary (11) found that small molecular weight bivalent 
haptens frequently provoked passive cutaneous 
anaphylaxis reactions in experimental animals, whereas 
larger molecular weight haptens had no effect. They 
concluded that molecular size is an important factor 
controlling the absorption of a given protein from the 
gut. 
In 1959 Danforth and Moore demonstrated the 
production of hypoglycaemia in rats following injection 
of insulin into ligated intestinal loops (12). There 
have been many attempts since, to increase the 
intestinal absorption of insulin and other proteins and 
macromolecules using a variety of formulations. Only 
limited success has been achieved and much of the data 
generated are confusing and contradictory. 
In early efforts to promote absorption, proteins were 
coadministered with agents which prevented proteolysis 
such as Aprotinin (trasylo1) (13) and pancreatic 
trypsin inhibitors (12). Whilst there was some increase 
in absorption, for a significant effect to be achieved 
large quantities of protein had to be administered. 
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Enzyme Inhibitors 
Absorption enhancers 
Lipid carrier systems 
hrtlculate carrier systems 
~ n c r e a t l c c trypsin Inhibitors 
tr .. ylol 
Ionic surfactants 
non-Ionic surfactlnts 
sallcylates 
Uposomes 
mixed bile salt micelles 
oIl-ln-water emulsions 
wlter-In-oll-In-w.ter emulsions 
nanopartlcles 
Ref.No. 
12 
13 
n, 
16, 
11 
15 
17 
19-26 
29, 30 
31, 32 
33-38 
38, 39 
Table 1.1. Approaches used in attempts to enhance the 
absorption of macromolecules across the gut. 
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Alternative approaches that have been investigated 
include the use of absorption enhancers, lipid carrier 
systems and particulate carriers (Table 1.1.). However, 
these studies did not really deal with the possible 
immunological consequences of enhanced macromolecular 
absorption. 
1.2. Attempts to enhance absorption. 
1.2.1. Absorption enhancers 
Some early workers used ionic surfactants to enhance 
the absorption of insulin, but these agents were found 
to irritate the gastric mucosa (14). More success was 
achieved with non-ionic surfactants ego Brij (15,16) 
and Cetomacrogol (17), but high concentrations of 
insulin were required. 
Sodium-5-methoxysalicylate has been shown to enhance 
insulin absorption after intraduodenal administration 
to rats. But high concentrations of salicylate 
(>6mg/rat) are required at the absorption site, so a 
rectal formulation, where dilution effects are reduced, 
is more suitable (18). 
1.2.2. Lipid carrier systems 
1.2.2.1. Liposomes 
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Liposomal systems have been used by several groups 
(19-23) in attempts to increase the absorption of 
macromolecules. Much of this work has been associated 
with the attempted development of an orally effective 
formulation of insulin. 
In a recent comprehensive review on liposomes, 
Woodley (24) concluded that they are not suitable for 
the delivery of insulin and other macromolecules in 
humans, as only limited and variable absorption has 
been achieved with this type of formulation. However 
evidence exists which indicates that liposomes can act 
as immunological adjuvants, potentiating the immune 
response to orally co-administered antigens (25-28). 
This is discussed further in chapter 4. 
1.2.2.2. Mixed micelles 
The duodenal absorption of heparin in rats was 
enhanced when administered in a mixed micellar 
solution, probably due to enhanced fluidity and 
permeability of the intestinal wall (29). However, 
these systems were much more effective in the large 
intestine, due to the reduction of dilution effects at 
this site (30). 
1.2.2.3. Emulsions 
-8-
The enhanced intestinal absorption of heparin, in 
oil-in-water emulsions (31,32) in rats and gerbils, and 
of insulin, in water-in-oil-in-water double emulsions 
(33-37) in rats has been reported. These lipid 
formulations were thought to promote absorption by 
protecting the proteins from degradation, but the 
possible effect of the surfactants on the intestinal 
membrane was not considered. 
1.2.3.Particulate carriers 
Couvreur et ale (38) orally administered to rats, 
insulin adsorbed onto a range of hydrolysable 
polyalkylcyanoacrylate nanoparticles. The nanoparticles 
were spherical with a mean diameter of 200nm and a 
highly porous structure. No hypoglycaemic effect was 
observed. Oppenheim et al. (39) achieved more success 
by using n a n o p a r t i c l ~ s s (200nm) of insulin produced by 
desolvation and cross linking with glutaraldehyde of 
neutral insulin injection. Following intrajejunal 
administration, a hypoglycaemic response was detected 
in both rats and mice but the site and mechanism of 
absorption were unknown. 
Although many investigations have clearly 
demonstrated that intact proteins and macromolecules 
can be absorbed across the gastrointestinal mucosa, the 
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quantity that is absorbed is small. Despite 
considerable efforts to promote uptake by the use of 
suitable formulations, the extent of absorption that 
can be achieved is still insufficient to produce 
therapeutic plasma levels of compounds such as insulin 
following oral administration. 
1.3. Mechanisms of protein and macromolecular 
absorption. 
1.3.1. Macromolecular absorption in the immature 
intestine. 
The permeability of the gastrointestinal mucosa to 
proteins during the perinatal period seems to be 
related to a number of factors. These include decreased 
breakdown of macromolecules, increased attachment of 
molecules to the intestinal epithelial surface and less 
inhibition of uptake by immunoglobulins in the milk and 
colostrum. Within the same animal the mechanism and 
capacity for macromolecular uptake by the enterocytes 
may change from one region of the gut to another. In 
addition there are species related differences in 
permeability. The rat and the mouse exhibit selective 
absorption, involving a pH dependent IgG (Fc) receptor 
in the proximal small intestine, during the first two 
and three weeks of life respectively (40). Both show 
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rapid proteolysis from birth and no proteinuria. In 
contrast, in ungulates and carnivores, absorption is 
non selective, almost every colostral protein is 
absorbed, proteolysis is suppressed by colostral 
trypsin inhibitor and there is physiological 
proteinuria. This lasts only for the first two to three 
days of life, although the enterocytes will internalise 
macromolecules for longer periods they will not 
transport them. 
There appear to be two mechanisms possible for the 
absorption of proteins through the neonatal intestine, 
either receptor or non-receptor mediated transport 
(Figure 1.1.). The receptor mediated transport involves 
the formation of coated pits and vesicles (41,42). It 
is thought that specific protein receptors are present 
in the walls of the microvilli and that a substance 
called clathrin floats freely within the structure of 
the microvilli. When a macromolecule binds to its 
specific receptor, the clathrin binds to the other side 
of the same receptor and a complex is formed. This 
moves to the base of the microvillus where a clathrin 
coated pit is formed which then breaks free to form a 
distinct vesicle. The vesicles traverse the cell and 
undergo exocytosis to release the macromolecule into 
the extracellular space (43,44). The clathrin coat 
apparently protects the vesicle from fusing with the 
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Figure 1.1. Schematic diagram of the selective and 
non-selective mechanisms for the absorption of 
macromolecules in the immature gut. 
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lysosome. The cells in the upper areas of the intestine 
display receptor mediated transport whilst the cells 
lower down in the small intestine do not. Non-receptor 
mediated transport is thought to occur via 
non-selective apical tubular systems in the cell 
surface. The end of these tubules pinches off to form 
vesicles which pass through the cell and are exocytosed 
(43,44). Only a small proportion of the macromolecules 
absorbed by the non-receptor mediated transport 
mechanism actually reaches the systemic circulation, 
the rest undergoes digestion by lysosomal enzymes after 
fusion with the cell lysosomes. 
The extensive uptake of macromolecules ceases with 
the development of the intestinal immunological and 
non-immunological host defences and maturation of the 
intestinal epithelial cells. As the cells mature they 
no longer internalise macromolecules, a process known 
as closure. In humans closure is more subtle than in 
other animals and the major changes in absorption 
properties of the intestine are thought to occur in 
utero. 
1.3.2. Macromolecular absorption in the mature 
intestine. 
Following closure the uptake and transmission of 
macromolecules does not cease completely, several 
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mechanisms exist by which such compounds can still 
penetrate the intestinal mucosa. 
Combined morphological and physiological experiments 
have shown that the mature small intestinal epithelial 
cell is able to engulf macromolecules by an endocytic 
process indistinguishable from the pinocytosis 
described for human macrophages (Figure 1.2.). The 
initial event in this process is the adsorption of 
large molecules onto components of the microvillus 
membrane of intestinal absorptive cells. When a 
sufficient concentration of molecules is in contact 
with the cell membrane invagination occurs and small 
membrane bound vesicles (phagosomes) are formed. The 
macromolecules then migrate within the phagosomes to 
the supranuclear region of the cell where they coalesce 
with lysosomes to form large vacuoles called 
phagolysosomes. Within these structures intracellular 
digestion occurs but small quantities of ingested 
molecules are thought to escape degradation. The 
phagolysosomes migrate to the basal surface of the cell 
and release their contents including any non-degraded 
macromolecules, into the interstitial space by a 
reversal of the pinocytotic process. In vitro studies 
on the intestinal absorption of tritiated horseradish 
peroxidase in adult rabbit jejunum suggested the 
existence of at least two functional pathways for 
-14-
INtIA-<lWJlAI 'A_AY 
...... __ .. n _ - + - ~ . .
~ _ . . . . . . . 00 
"...ua 11 
1I1U-ClI..LUlAl , ATIMA Y 1 
• 
t)wdonl 
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mechanisms for the absorption of macromolecules in the 
mature gut. 
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intestinal protein transport (45). The main route 
involves endocytosis with striking intracellular 
degradation as described above. It was estimated that 
67-97% of absorbed HRP was degraded whilst crossing the 
tissue from the mucosa to serosa. A second direct 
pathway exists which allowed HRP to cross the mucosal 
barrier intact but that required the structural and 
metabolic integrity of the epithelial cell. The 
location of this direct route is not known and may be 
either intracellular or intercellular through tight 
junctions. 
Further work with HRP demonstrated that after 
infusion into the rat jejunum through an indwelling 
catheter, small but significant amounts of protein were 
consistently transmitted across the gut and penetrated 
into lymph and portal blood (I). A number of studies 
with compounds other than HRP has also shown that the 
lymphatic system can contribute significantly to the 
transport of absorbed macromolecules into the systemic 
circulation. As early as 1936 Alexander et al. (46) 
found that egg white protein, absorbed intact from the 
intestinal tract of dogs, reached the vascular 
compartment via the lymphatic vessels. May and Whaler 
(47) using Clostridium botulinum toxin A (molecular 
weight 900,000) showed that in rats, rabbits and mice 
higher titres of toxin were often present in the 
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thoracic duct lymph than the peripheral blood, 
indicating that absorption was occuring via the 
lymphatic system. A similar conclusion was reached by 
Gans and Matsumoto (48) after investigating the 
absorption of Escherichia coli endotoxin in rats. 
Not all macromolecules and proteins that are absorbed 
from the intestinal lumen pass directly into the 
lymphatic system. The macromolecule ferritin is taken 
up by the intestinal absorptive cells and has been 
found, both as aggregates and as individual particles, 
in macrophages, fibrocytes and endothelial cells of the 
lamina propria (49). Investigations into the absorption 
p ~ t h w a y y of heparin and insulin have shown that a 
greater percentage of both molecules is absorbed into 
the portal vein (32,50). The proportion of the absorbed 
dose which passes into the lymphatic vessels can vary 
considerably. In a series of experiments Katayama and 
Fujata (51,52) examined the intestinal absorption of 
three enzymatic proteins, l'2,-(3 H)-Coenzyme Q10 
3 131 . (H-QIO), I labelled elastase (molecular welght 
131 24,000), and I-lysozyme. The absorption of each 
molecule was low, only 0.05-2.06% of the total dose, 
but the importance of the lymphatic vessels in the 
absorption process varied considerably. Eighty per cent 
of the absorbed 3H- QIO was recovered from the lymph, 
predominantly in the chylomicron fraction (lipoprotein 
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units), whereas the portal vein was the main absorption 
131 pathway for I-lysozyme. During the first 7 hours 
after administration of 13lI-elastase the lymph levels 
were 10 times higher than the plasma levels and 36% of 
the absorbed dose was calculated to have been absorbed 
via the lymphatic system. The authors concluded that 
absorption into the lymphatic vessels was dependent on 
the physico-chemical properties of the macromolecules. 
They suggested that further work was required to 
determine the relationship between these 
characteristics of macromolecules and uptake into the 
lymphatic system. 
Within the intestinal region blood flow is 
approximately 500 times that of lymph flow. This means 
that a larger percentage of absorbed material will move 
into the portal vein unless there is a selective 
mechanism for uptake into the lymphatic vessels. Some 
understanding of the factors controlling absorption 
into the lymphatic vessels can be obtained by 
considering the physiological functions of this system. 
Its primary function is the collection of tissue fluid 
from extracellular spaces, which is then returned to 
the vascular compartment via the lymphatic system. 
Plasma proteins in the tissue fluid which are too large 
to permeate through the capillary pores back into the 
blood vessels are returned to the systemic circulation 
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by the same route. The lymphatic vessels are therefore 
structures adapted to the collection and transportation 
of large molecules. It is likely that absorbed 
macromolecules which are too large to permeate the 
intestinal blood capillaries will be absorbed into the 
mesenteric lymph duct. In the small intestinal region 
the lymphatic vessels also have a specialised function, 
that of fat absorption. Lipid digestion products that 
are too lipophilic to readily disperse in the aqueous 
environment of the blood are packaged into lipoprotein 
units (very low density lipoproteins and chylomicrons) 
which pass into the lymph. Lipophilic nutrients such as 
cholesterol and the fat soluble vitamins associate with 
the chylomicrons within the mucosal cell and are 
therefore transported via the lymphatic system. It has 
been shown that highly lipophilic exogenous compounds 
can also be selectively absorbed into the l y m ~ h a t i c c
vessels in the same way. The presence of the coenzyme 
3H- QIO in the chylomicron fraction of the lymph 
suggests that this molecule is highly lipophilic and 
therefore associated with the chylomicrons within the 
mucosal cell and was selectively absorbed into the 
lymphatic vessels. Thus the uptake of macromolecules 
into the lymphatic vessels will be dependent on a 
number of physico-chemical properties including 
lipophilicity, molecular size and molecular 
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configuration, as was concluded by Katayama and Fujata 
(51,52). Macromolecules in the lymph will rapidly come 
into contact with the lymphocytes in the draining lymph 
nodes which are the inducers of immune responses. 
Highly specialised mechanisms also exist along the 
intestinal tract for the absorption of specific 
macromolecules. Vitamin B12 cobalamin is a dietary 
coenzyme required to sustain life in all mammalian 
species. It is transported across the ileal enterocytes 
to the portal circulation by a process involving a 
specific ileal mucosal receptor. In the gut vitamin B12 
binds to a specific gastric glycoprotein called 
intrinsic factor (IF), which has an estimated molecular 
weight of 50,000-70,000 and is secreted by the parietal 
cells (53). The binding of vitamin B12 and IF is rapid 
and the complex formed is very stable over a wide range 
of pH conditions and in the presence of gut enzymes 
(54). When the vitamin B12-IF complex reaches the 
ileum, it in turn binds specifically to a receptor 
present on the surface of the enterocytes. The 
attachment of the complex to its receptor is calcium 
dependent, does not require metabolic energy and occurs 
preferentially between pH 6.0 and 8.0 (55). The actual 
uptake of the complex by the ileal enterocyte is poorly 
understood. It is a slow (>3hr), energy dependent 
process (56), and seems likely to involve some sort of 
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adsorptive endocytic mechanism. It is possible that 
similar mechanisms exist for the absorption of other 
specific macromolecules which as yet are unknown. 
The uptake of some plant and bacterial protein toxins 
is initiated by binding to the surface of the 
enterocytes. Many of these toxins consist of two 
subunits, with subunit A being a lectin which 
facilitates the entry of the toxic B subunit into the 
cell (40). Several viruses ego influenza virus, and 
bacteria ego E.Coli, anchor themselves on the cell with 
lectins before penetration. 
Another specialised mechanism exists within the 
gastrointestinal tract by which small quantities of 
macromolecules (antigens) may be absorbed. Absorption 
occurs via the M-cells which are associated with the 
lymphoid tissue of the gut and can result in the 
generation of an immune response. This process is 
discussed in detail in section 1.5. 
1.4. Intestinal absorption of particles. 
Since 1850 a number of researchers have reported the 
passage of particulate material across the adult small 
intestine. A series of studies by Volkheimer (57-62) 
indicated that diatoms, pollens, spores, cellulose 
particles, plant cells and starch grains can cross the 
intestinal mucosa in man by a process called 
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persorption. Many more particulates have been shown to 
cross the intestinal mucosa of animals and particulates 
of intestinal origin have been reportedly found in 
urine and cerebrospinal fluid (60), and in the 
cordblood of newborn human infants after ingestion of 
the particulates by the mothers (62). 
Volkheimer described persorption as a mechanical 
process whereby "large", solid particles are 'kneaded' 
through the epithelial layer into subjacent tissues. 
The particles passed between the epithelial cells, 
particularly in areas of desquamation. Persorbability 
was limited by size and hardness, hard particles in the 
range 7 - 7 0 ~ m m giving the best results although 
persorption still occurred in the size range 5-150pm. 
Mechanical factors are thought to be responsible for 
persorption as drugs which increased gastrointestinal 
motility also increased the rate of persorption, the 
reverse was also true for drugs that reduced gastric 
motility (58). 
A mechanism for persorption was proposed by Luckey 
(63). As the villus contracts like a piston, the 
pressure pushes lymph from the lacteals into the 
lymphatic vessels. This adds to the pressure already 
being exerted on the epithelial cells by the 
reproducing cells around the base of the villus. Any 
loose cells in the extrusion zone of the villus are 
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forced off the basement membrane in a mini eruption. 
Relaxation of the villus produces a relative difference 
in pressure allowing a micro-implosion to draw 
particulate matter through the wound created by the 
discarded epithelial cells. This mechanism agrees with 
the theory proposed by Volkheimer, that persorption 
occurs particularly through areas of desquamation, such 
as at the tips of the villi. 
It was suggested that persorbed particles were 
transported mainly via the lymphatic system with some 
portal transport. The distribution of particles between 
the two routes is likely to depend on particle size 
with the smaller particles being carried mainly by 
portal circulation and the larger ones by the lymph 
(61). The same study showed that persorption decreases 
with increasing age of the animal under test. Various 
peaks of persorption were demonstrated after particular 
age intervals. 
Many scientists consider this line of research to be 
very limited, since it deals with a passive process and 
not an active one. The results quoted have not been 
accepted by all researchers. 
More recently the accumulation of certain inert 
particles in mouse Peyer's patches (PP) after ingestion 
has been demonstrated. Chronic experiments, in which 
mice were fed carbon (20-50nm), or latex (2pm) in their 
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drinking water led to the uptake and retention of 
particles in PP (64-67) • Absorbed particles reached 
all parts of the PP follicle, including the germinal 
centre and were accumulated in macrophages. The 
macrophages were thought to be responsible for the 
transport of particles throughout the PP (67-70). 
However, there was little evidence of transport of 
particles from the PP to the bloodstream. In another 
study, 5.7pm and 1 5 ~ m m particles were not found in blood 
or reticuloendothelial organs up to four hours after 
ingestion, although some 5.7pm particles were recovered 
from the mesenteric lymph nodes and the lungs after 
long term ingestion (64). It has been suggested that 
particles which bypass, or are released from, 
mesenteric nodes are trapped in the lungs and that some 
are carried into the airways by pulmonary macrophages 
and excreted via the mucociliary "elevator system" 
(71 ) • 
The uptake of 2pm latex particles has been shown to 
occur even in the complete absence of bacteria, this 
demonstrates that bacterial activity is not necessary 
for uptake (72). It has been suggested that surface 
characteristics as well as particle size governs 
accumulation in PP, with hydrophobic particles being 
taken up more easily than hydrophilic ones (71,73). 
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In healthy human volunteers Candida albicans cells 
were shown to penetrate the intestinal wall following 
oral administration, probably by the mechanism of 
persorption, and to reach the blood and urine (74). 
Further studies in dogs and primates confirmed that 
Candida albicans cells are persorbed across an intact 
intestinal mucosa (75). Persorption of living candida 
may account for certain cases of systemic candidiasis 
which have followed oral administration of large doses 
of antibiotics. 
It is evident that particulate material may be 
absorbed across the gastrointestinal tract and that the 
PP is a less effective barrier than the rest of the 
epithelium. The precise mechanisms involved in this 
process and the fate of the absorbed particulates have 
not yet been clearly elucidated. 
1.5. Gut associated lymphoid tissue (GALT). 
The gut contains as much lymphoid tissue as the 
spleen and probably synthesises more immunoglobulin 
than any single organ. The gut associated lymphoid 
tissue is distributed in four recognised anatomical 
locations, a) the lamina propria, which contains many 
cell types, a large proportion being IgA-secreting 
plasma cells, b) the intraepithelial lymphocytes, 
dispersed between the epithelial cells of the mucosal 
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membrane, c) the isolated lymphoid follicles, which are 
present throughout the small intestine and colon, and 
d) the PP, which are clusters of lymphoid follicles 
also found along the length of the small intestine. The 
lymphoid tissue in the lamina propria and the 
intra-epithelial lymphocytes are known as the diffuse 
lymphoid tissue (76). The lymphoid tissue responsible 
for the initiation of the immune response is found in 
both the isolated lymphoid follicles and the Peyer's 
Patches. 
1.5.1. Diffuse lymphoid tissue 
The lamina propria contains large numbers of 
macrophages, neutrophils, eosinophils, plasma cells and 
mast cells. These cells are all absent at birth but 
gradually accumulate during the first few weeks of life 
probably in response to extrinsic antigens. The cells 
in the lamina propria are thought to regulate the 
function of the overlying epithelium through 
immunological reactions (77). 
The epithelium lining the gastrointestinal tract 
contains up to 20% of non-epithelial cells, most of 
which are intraepithelial lymphocytes (IEL). In the 
stomach and proximal small intestine over 95% of lEL 
are T lymphocytes, whereas in the colon and rectum 
85-95% are T lymphocytes and the remainder are B 
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lymphocytes. The role of the IEL in the mucosa is 
unclear but their numbers are greatly reduced in germ 
free animals. It is probable that they are activated 
lymphocytes produced by a cell mediated response to 
intraluminal antigens, and they may play an important 
role in processing intraluminal antigens (78). 
T lymphocytes appear capable of crossing the basement 
membrane in both directions (79). They may transport 
antigens within the cell or bound to the cell surface. 
Owen, Bhalla and Apple (aO) observed morphologically 
intact lymphoid cells migrating through discontinuities 
in the epithelium produced by dead and damaged 
epithelial cells. They also observed lymphocytes 
extending through pores surrounded by intact M-ce11s 
maintaining tight junctions with adjacent enterocytes, 
but were unable to identify lymphocytes migrating from 
the lumen back into the epithelium. 
1.5.2. Peyer's patches (PP). 
Lymphoid follicles grouped in the submucosa of the 
small intestine and devoid of afferent lymphatics are 
called Peyer's patches. Each lymphoid follicle has a 
dome like appearance on the luminal surface (76). The 
distribution of PP varies between species, in man they 
are more cornmon in the ileum (al). The epithelium 
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covering PP usually lacks goblet cells and is made up 
of columnar cells interdigitating with M-cells (82). 
The lymphoid tissue of the PP forms four anatomically 
separate areas a) the follicle, which contains a 
germinal centre, b) the dome overlying the follicle, c) 
a thin rim of cells below the germinal centre, and d) 
an interfollicular area (Figure 1.3.). The adult PP 
consists of 40-70% B lymphocytes and 11-40% T cells 
which are differentially distributed. The B lymphocytes 
are found primarily in the germinal centre, whereas T 
cells predominate in the dome and interfollicular 
areas. This distribution results from the different 
migratory patterns of the cells. T cells migrate 
preferentially to the peripheral lymph nodes, whereas B 
cells demonstrate a relative preference for PP and the 
spleen. This specific localization is independent of 
the lymphocyte source and is determined by recognition 
of organ specific markers on the endothelial cells of 
high endothelial venules (83). 
There is evidence to suggest the presence of duct 
associated lymphoid tissue in the minor salivary 
glands, similiar to the GALT, which is accessible via 
the salivary ducts (84). Perhaps this indicates that 
local stimulation is important, particularly for 
salivary immune responses. 
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1.6. M-cells. 
Specialised epithelial cells called M-cells, are 
found interdispersed amongst the other epithelial cells 
of the lymphoid follicle dome (8S). M-cells are 
modified to absorb antigens from the gastrointestinal 
lumen and to deliver them to the lymphoid tissue where 
an immune response is stimulated. Clusters of M-cells 
have been identified in many species overlying the 
lymphoid follicles in the gut (85-87); similar cells 
have been found in other areas. Lymphoepithelial cells 
with characteristics similiar to intestinal M-cells are 
found in the epithelium overlying aggregated nodular 
lymphoid tissue in the respiratory tract (88-90). 
Bockman and Cooper (87) demonstrated uptake of ferritin 
into the Peyer's Patches of mouse intestine, the Bursa 
of Fabricius of chickens and the appendix of rabbits. 
M-cells have also been called follicle associated 
epithelial cells due to their general association with 
lymphoid follicles (91). 
M-cells are both functionally and morphologically 
different from columnar epithelial cells (82). If cell 
specific markers can be identified on the M-cells it 
may enable delivery of macromolecules to a site 
specifically developed for the absorption of such 
molecules. It seems unlikely that M-cells operate as 
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antigen presenting cells. It has been suggested that 
ordinary enterocytes can function as antigen presenting 
cells (92,93), but this is unlikely to be important 
physiologically since the ordinary enterocytes are 
isolated from lymphoid cells. M-cell function is 
probably more aptly described as antigen sampling. 
1.6.1.Function 
M-cells transport many macromolecules and 
micro-organisms from the gastrointestinal lumen to the 
underlying lymphoid tissue (Table 1.2.). It is not 
known whether M-cells act as passive conduits for these 
antigens or whether they process the antigens in some 
way. 
A clathrin-like coated pit has been demonstrated on 
some endosomes of M-cells suggesting that a type of 
receptor mediated transport is involved (94), but the 
bulk uptake of markers such as HRP and ferritin 
indicate that not all uptake is receptor mediated. HRP 
has been shown to bind to the surface of M-cells 
entering the cells via a pinocytic process forming 
apical vesicles (Figure 1.4.). It is transported across 
the cell within the vesicles and released, by 
exocytosis, into the extracellular space between the 
M-cells and the enfolded intrusive cells in the central 
hollow (see below). The HRP then binds to the surface 
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MACROMOLECULES 
Native ferritin 
Cationised ferritin 
Horseradish peroxidase 
Ricinus communis agglutinin II 
Wheatgerm agglutinin 
MICRO-ORCANISMS 
Viruses - Reovirus type 1 
Reovirus type 2 
aacteria - Mycobacteria 
Chlamydia 
Vibrio cholera 
Table 1.2. Materials known to be transported by 
M-cells. 
-32-
o o 
• • 
o 
Short Irf9IIr:.,....,-+*=-__ 
IIIlcrwllll 
11M! -1c:rdoIds 
...,. wslcles--I---";;:;" 
Cllntnl hollow ~ ~M CIIII-..--------4 
Intruslw cells ) 
• 
• 
•• 
o 
o 
'\;7--------I---plnocyt)sls ~ ~
Inagan 
r:"Ir--------.,I---'WlSlcullr transport 
~ ~ Intlgln 1 ' U ' o u ~ ' 1 1
.,. CIIII 
, ~ ~..... ",L----IIf---aocytcJsls ~ ~ InUlJIn 
Into .xtrallullr SplCt 
A----f---Migntion ~ ~ Iymphocytt 
______ I n ~ ~ Intirfolliculir 
1m 
Figure 1.4. Schematic diagram illustrating the process 
by which antigens are absorbed via M-cells. 
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of, and is subsequently taken up by, lymphocytes and 
macrophages (86). 
Histochemical studies have demonstrated a 
preferential uptake of HRP into intestinal M-cells when 
low concentrations of HRP are present. If larger 
amounts of HRP are present a more generalised uptake by 
all epithelial cells occurs by the mechanisms described 
previously (section 1.3.2.). This suggests that the 
mode of antigen uptake and penetration in the gut may 
depend on the antigen concentration present. At 
physiological, or lower levels of lumenal antigen, the 
specialized uptake pathway is preferred, whereas at 
higher antigen levels a more generalized uptake of 
antigen takes place. The mechanism of specialized 
antigen uptake by the gut seems to provide an important 
specific access route for intestinal antigens to reach 
lymphoid tissues and thereby stimulate the local immune 
system. 
Materials much larger than HRP are also transported 
by the M-cells. It has been shown that this is the site 
where reoviruses penetrate the intestinal epithelium 
(95,96), Reovirus type 1 adheres specifically to 
M-cells. M-cells have also been shown to be capable of 
phagocytosing and transporting intact Vibrio cholerae, 
which are curved rods of size 1.5 by 3pm (97,99). The 
increased capacity of M-cells to take up and transport 
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various substances has not been fully explained. The 
thinner glycocalyx over the cells may simply make them 
more accessible than ordinary enterocytes, or perhaps 
the M-cell surface is more sticky due to the presence 
of polyvalent adhesins. This latter idea is supported 
by the fact that some micro organisms bind 
preferentially to M-cells (95,99,105). 
1.6.2. Morphology. 
M-cel1s display a number of characteristic features 
which distinguish them from neighbouring cells. The 
surface lacks glycocalyx (98,100) and is characterised 
by microfolds and short irregular microvilli that are 
often wider and fewer in number than those on 
absorptive cells. The cells are cubical in shape rather 
than columnar (82). Vesicles are abundant in the apical 
cytoplasm and M-cells have been shown to endocytose and 
transport macromolecules (85,87,101,102) and 
micro-organisms (95,97,99,103) through the cell. The 
mitochondria are more electron dense than those in 
other cells and they are located in the apical region 
of the cytoplasm, which correlates with the transport 
function of the M-cells. There is also a deficiency of 
lysosomal material, but other organelles in M-cells are 
similiar to those in surrounding absorptive cells 
(104). The mature M-cell has a thin bridge of apical 
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cytoplasm and a basally located nucleus. Its cytoplasm 
surrounds one or more intrusive cells, which are 
usually lymphocytes (86), lymphoblasts (98), or 
macrophages (97,103), but occasionally plasma cells 
(98) or polymorphonuclear leucocytes (105). These cells 
are not within the M-cell cytoplasm, but are in the 
intercellular space that indents the cytoplasm, forming 
a 'central hollow' (80). 
Various theories have been proposed to explain the 
origins of M-cel1s. There is some evidence to support 
the suggestion that the cells differentiate from mature 
absorptive cells on the upper part of the dome 
(86,98,106,107). However it is now generally accepted 
that many, if not all, M-cells differentiate directly 
from undifferentiated cells of the crypts encircling 
Peyer's Patches (91). There are two major subsets of 
M-cel1s, which have been termed mature and immature on 
the basis of their differing structural features (108). 
Although the subsets differ structurally, they are both 
termed M-cells because they display the same binding 
and functional characteristics, namely: selective 
adsorption of reovirus type 1, internalisation of 
intraluminally administered ferritin, absence of lipid 
uptake from micellar solutions and apical membranes 
rich in cholesterol (94,108). It has been postulated 
that lymphocytes influence differentiation of M-cells 
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from immature to mature cells in the epithelium 
overlying the lymphoid follicles, as the mature cells 
seem to be closely associated with lymphoid cells 
(98,106). 
The role of M-cells must be put into perspective 
relative to ordinary enterocytes, which are much more 
abundant and are also capable of the uptake of 
macromolecules. Material taken up into enterocytes will 
be extensively degraded by lysosomal enzymes during 
passage through the cell, whereas M-cell uptake is not 
followed by degradation. Also, material taken up by 
M-cells is very likely to be presented to 
immunocompetent cells because of the close association 
of these cells. Material absorbed by the enterocyte 
wiil gain access to the blood or lymph, where it is 
rapidly filtered out of the system. Therefore, the 
uptake of proteins by 'ordinary enterocytes may lead to 
the induction of a systemic immune response, whereas 
the uptake of proteins by M-cells may result in the 
induction of a secretory immune response. 
Comparisons of the apical membranes of M-cells and 
absorptive cells have been made in attempts to explain 
their varying functions. Histochemical studies have 
shown that the apical membrane of the M-cell has less 
alkaline phosphatase activity, but more esterase 
activity, than absorptive cells (107,109). Various 
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ferritin labelled lectins, including ricinus communis 
agglutinins I and II, concanavalin A and dolichos 
biflorus, bind sparsely to both M-cells and absorptive 
cells in organ culture. Whereas wheatqerm agglutinin, 
which has an affinity for terminal sialic acid residues 
and oligomeric N-acetyl-D-glucosamine, binds more 
avidly to M-cells than to the surrounding absorptive 
cells in unfixed tissue (110). In fixed PP the binding 
is the same for M-cells and absorptive cells for all 
lectins tested (109). Staining with ruthenium red has 
confirmed that M-cells have a less elaborate glycocalyx 
than absorptive cells (105). Exposure of fixed 
intestinal tissue to the polyene antibiotic filipin, 
which binds cholesterol in a 1:1 ratio, reveals an 
abundance of filipin cholesterol complexes in the 
M-cell apical membrane, except in areas involved in 
endocytosis (110). M-c.ells have also been shown to have 
a low protein to lipid ratio (94). Further studies of 
the M-cell apical surface may help to explain how the 
cells bind antigens prior to their uptake. This 
knowledge would be of great benefit in attempts to bind 
material specifically to M-cells and to promote their 
subsequent uptake. 
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1.7. The immune response 
The peyer's Patches via the M-cells, allow the 
migrating lymphoid cells to come into contact with 
intestinally derived antigens. After absorption, 
antigens are likely to be endocytosed by macrophages in 
the PP. Most of this antigen will be degraded rapidly 
in the phagolysosomes, however, part of the antigen is 
then expressed on the macrophage surface and will be 
recognised by T helper cells. Macrophages are very 
important in the presentation of antigen to T helper 
cells, because of their ability to regulate expression 
of Ia (histocompatibility) determinants and to process 
both particulate and soluble antigens (Ill). Through 
this mechanism, an immune response to the antigen can 
be initiated. Primed lymphocytes pass from the PP into 
the submucosal lymphatics and drain via the mesenteric 
vessels into the thoracic duct. Partly matured 
lymphocytes return to the mucosal secretory sites, 
including the lamina propria where they mature and 
secrete immunoglobulins (Figure 1.5.). 
Peyer's Patches contain modified post capillary 
venules that allow lymphocytes to escape into the 
lymphoid tissue. Efferent lymphatics surround Peyer's 
Patches which drain predominantly into the mesenteric 
nodes but a few vessels drain directly into the lamina 
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involved in the immune response to intestinally 
absorbed antigen. 
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propria. However there are no afferent lymphatic 
vessels from the lamina propria to the Peyer's Patch to 
allow passage of cells in the reverse direction. 
The majority of lymphocytes reaching the thoracic 
duct are primed to produce IgA (IgA bearing 
lymphocytes). The B lymphocytes of the Peyer's Patches 
give rise mainly to IgA bearing lymphocytes because 
there is antigen induced isotype switching of the B 
cells in situ (112). The switch T cells in the Peyer's 
Patches operate as true switch cells, controlling DNA 
recombination events, rather than as classical helper 
cells which act to expand already differentiated cells 
(113). The B cells mature into plasma cells (IgA 
secreting cells) only when they leave the restrictive 
environment of the Peyer's Patches. It is not known how 
the Peyer's Patches provide a special milieu in which 
isotype switching without terminal maturation of the B 
lymphocytes to plasma cells can occur, but the T 
suppressor cells in the Peyer's Patches certainly have 
a role to play here. 
The primed lymphocytes may undergo further processing 
in other lymphoid organs such as the spleen. The partly 
matured plasma cells (lymphoblasts) return to the 
lamina propria or other mucosal sites and then 
differentiate into fully mature IgA secreting plasma 
cells or effector T cells. There appears to be some 
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component of the environment which causes lymphoblasts 
to selectively mature at the mucosal sites. It has been 
suggested that the secretory component (described 
below) or re-exposure to the lumenal antigen may be 
important in this process. Experimental evidence 
indicates that antigenic re-stimulation of the primed 
lymphoblasts is particularly important in the salivary 
gland (114). Band T cells, primed in the gut lymphoid 
follicles, migrate to mucosal surfaces in many 
locations in the body including the gastrointestinal 
tract, lung, breast, cervix, uterus and salivary and 
lacrimal glands. This has led to the concept of the 
common mucosal immune system (115). 
The main immunoglobulin produced from the plasma 
cells of the lamina propria is IgA, but IgM, IgG, IgO 
and IgE cells are also found. IgA is found in the 
serum, but is mainly found in the secretions of all 
mucosal sites in the body. In animal species it is 
mainly dimeric, consisting of two IgA monomers bound 
together by a J chain, the IgA monomer and J chain are 
both synthesised by submucosal plasma cells. In humans, 
secretory IgA is dimeric, but 90% of serum IgA is 
monomeric. It is possible that in humans both monomeric 
and dimeric IgA is synthesized in the intestine and 
then diffuse or are transported either into the serum 
and to the mucosal surfaces. The secretory component 
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synthesised by the glandular epithelial cells is also 
found at the mucosal site. This transports IgA across 
the epithelial cells and protects it from proteolysis 
in the gut lumen. 
Secretory immunoglobulins complexed with the 
glycocalyx on the surface of the intestinal epithelium 
forms a protective barrier against the penetration of 
micro-organisms (116). Binding to the gastrointestinal 
mucosa is a prerequisite for bacterial colonization. 
Secretory IgA combines with the bacterial antigens 
responsible for colonization and thereby helps to 
prevent it (79). Secretory IgA is effective at 
agglutinating bacteria because of its multiple valency, 
but it does not fix complement activated via the 
classical pathway. Several studies have shown a strong 
correlation between the presence of antibody in 
secretions and resistance to viral replication at 
mucosal surfaces. 
Local immune mechanisms may provide a control 
mechanism for limiting the intestinal absorption of 
intact macromolecules. Immune exclusion may protect the 
host from excessive absorption of many macromolecules 
by forming non-absorbable complexes on the mucosal 
surface, which may then be degraded (79). 
In rats dimeric IgA is rapidly transported from serum 
into bile via a saturable transport process. This 
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uptake mechanism is associated with the presence of 
secretory component in the hepatic parenchymal cells, 
which appears to act as receptor for the IgA 
(117,118). A similar mechanism also occurs in humans. 
At certain stages of lactation IgA is selectively 
transported from serum into ruminant milk via a 
transport mechanism dependent on the presence of 
secretory component in the mammary glands (119). These 
observations indicate that secretory component 
dependent removal of IgA from serum may be a feature of 
all mucosal sites. This could provide a compensatory 
mechanism to ensure that IgA reaches mucosal secretions 
even in the absence of local production. 
The secretory immune system of the body is thus 
adapted to prevent the uptake of large amounts of 
protein at mucosal surfaces. The presence of this 
immune response mechanism within the gastrointestinal 
tract may have a considerable effect on the chronic 
delivery of proteins via the oral route and requires 
further investigation. However it does raise the 
possibility of oral immunisation against pathogens, 
particularly against those which enter the body by the 
enteric route or proliferate in the gut. This may 
provide an attractive alternative to parenteral 
immunisation and may indeed be more appropriate for 
such organisms. Oral immunisation may also elicit 
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protective antibodies against organisms which infect 
other mucosal sites, such as the respiratory or the 
genital tract. 
Oral immunization alone would have several 
advantages over parenteral or combined therapy. Oral 
vaccines would be easy and inexpensive to administer 
and because of the relative absence of side effects 
would be far more acceptable to patients. The vaccines 
would not need to be highly purified, which would 
simplify preparation and in certain cases, eg. if the 
immunogenicity was enhanced by formulation factors, a 
killed organism might be appropriate, which would 
eliminate the difficulties of developing an attenuated 
strain. 
1.7.1. Attempts to enhance the immune response. 
A number of workers have considered methods of 
promoting the immune response to orally administered 
antigens. In 1969, it was suggested that the soluble or 
particulate nature of the antigen may affect the 
secretory antibody response produced after oral 
administration (160). Ebersole and Molinari 
demonstrated that oral immunisation with bacterial 
particulate antigens induced greater salivary antibody 
responses than the corresponding soluble antigens 
(161). More recently, Cox et a1. have confirmed that 
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greater secretory immune responses can be induced by 
oral immunisation of particulate as opposed to soluble 
antigens, but they only determined immune responses to 
a small molecular weight hapten (2,4-dinitrophenol or 
DNP) (159,163). They did not attempt to assess immune 
responses to the carrier protein. The soluble form of 
the antigen was more effective at priming parenterally 
for a subsequently enhanced secretory response than the 
particulate form (162). The greater secretory response 
after oral administration of particulate antigens may 
be due to a greater ability of particulate material to 
gain access to the tissue of the Peyer's Patch 
(95,137), to the greater uptake of particles by 
macrophages and other cell types after penetration of 
the PP, or to the persistence of the particles in the 
pp tissue after uptake (71). Soluble antigens are taken 
up to some extent by M-cel1s (74), but it has been 
suggested that a greater proportion of the soluble 
antigens will pass through the gut lamina propria into 
the venous system and initiate a systemic antibody 
response (164). It has also been suggested that the use 
of particulate bacterial antigens may result in an 
enhanced systemic response rather than tolerance as 
usually occurs with soluble antigens (148). 
As was mentioned in section 1.2.2. and will be 
discussed further in chapter 5, several studies have 
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indicated that liposomes are capable of enhancing the 
secretory immune response to orally administered 
antigens (25-28). 
1.8. Research aims. 
The overall aim of this project was to enhance the 
immune responses to a chosen model protein following 
oral administration. To achieve this, the protein was 
incorporated into, or adsorbed onto colloidal carriers. 
We were particularly interested in the secretory immune 
response, but in all experiments the serum response was 
assessed also. If the model protein can be protected 
from degradation in the gut and its uptake into, and 
transport across, gut epithelial cells can be enhanced, 
then the concentration of intact protein reaching the 
serosal side of the intestine is likely to be 
increased. This is likely to result in an enhanced 
serum immune response. If the amount of protein that 
gains access to PP tissue can be increased and the 
presentation to macrophages, lymphocytes and dendritic 
cells can be facilitated, then an enhanced secretory 
immune response is likely. The literature evidence 
indicates that PP uptake, macrophage presentation and 
immunogenicity will all be enhanced by rendering the 
protein particulate. Evidence suggests that the 
incorporation of proteins into colloidal carriers may 
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confer some protection on the proteins against 
degradation in the gut. 
The first objective of this work was to induce a 
significant positive salivary immune response and to 
demonstrate that the chosen immunoassay technique, an 
enzyme linked immunosorbent assay (ELISA), could detect 
a positive response in the saliva. Prior to this of 
course, the ELISA technique itself needed to be 
validated for the detection of antigen specific rat IgA 
and IgG. In early efforts to produce a significant 
positive salivary immune response, against DNP 
haptenated species, horse heart myoglobin (MYO) was 
chosen as the model protein carrier. It was chosen 
because of its proven ability to form a stable 
conjugate with DNP. However, due to the poor 
solubility of this conjugate, MYO was subsequently 
replaced with bovine gamma globulin (BGG). 
In later work involving oral administration, the DNP 
haptenated species were replaced by native protein 
models, since we wished to be able to determine if 
major structural or conformational changes of the 
protein ocurred during formulation. MYO was used in the 
early oral immunisation studies, but poor solubility 
limited its incorporation into the chosen formulations. 
Therefore, it was subsequently replaced by ovalbumin 
(OVA); this protein is cheap, soluble and is widely 
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used in immunological research. Since this material is 
isolated from eggs, it will not be contaminated with 
any extraneous immunoglobulins which might interfere in 
immunoassay procedures. 
The main objective of this project was to select 
several colloidal carriers as candidate pharmaceutical 
formulations which offered promise as orally 
administered immunological adjuvants either by virtue 
of their ability to confer protection on an entrapped 
protein and/or their ability to facilitate uptake by 
M-cells. Particles varying in size from O . 0 5 ~ m , , carbon 
(72), to 2 ~ m , , latex (73), have been shown to accumulate 
in PP during chronic feeding and organisms as large as 
1 . 5 ~ m m by 3pm have been shown to be transported by 
M-cells (97,99). It is not known which size of 
particulate might be expected to gain better access to 
the pp tissue. Polyacrylamide beads of about 1-3pm, 
after oral administration, have been shown to induce 
better secretory immune responses to material adsorbed 
to their surface than an equivalent dose of soluble 
material (159,163). Therefore, colloidal carriers which 
could be prepared at or below this size were selected 
for oral immunisation studies. Immunisation protocols 
and immunoassay procedures needed to be developed to 
generate reliable and reproducible levels of salivary 
antibody in the rat and to allow their quantitative 
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determination. The model protein needed to be 
incorporated into the chosen formulations and assays 
had to be developed to determine the extent of this 
incorporation. The effectiveness of the formulations as 
orally administered adjuvants was then assessed. 
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2. ASSAY METHODS. 
This chapter describes the immunoassay procedures 
adopted in attempts to determine salivary and sera 
immune responses to the model protein and the assay 
procedures adopted to determine the extent of its 
incorporation into, or adsorption onto the colloidal 
carriers. A method is also described which allowed us 
to demonstrate that the antigenicity of the model 
protein was unaltered by its association with the 
carriers. 
2.1. Enzyme linked immunosorbent assay. 
2.1.1. Introduction. 
An assay technique was required to determine 
antibodies in rat saliva and sera samples in order to 
assess quantitatively 'the effectiveness of the 
formulations as orally administered immunological 
adjuvants. A 'sandwich' type direct binding immunoassay 
was performed in which different isotypes of antibody 
in the rat samples competed for binding sites on the 
immobilised antigen and a second, enzyme-labelled, 
anti-antibody was used to determine the primary 
antibody titre. 
Enzyme labelled reagents are said to have several 
advantages over their equivalent radio-isotope labelled 
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counterparts, including long term stability, reduced 
health hazards, no licence required for use, no 
difficult safety precautions, easy disposal and simple 
inexpensive equipment required for read-out. However, 
enzyme labelled assays are not generally as sensitive 
as the radio labelled counterparts. 
Two groups of experimental animals were immunised 
with the chosen model antigens by intraperitoneal 
(i.p.) injection with a known adjuvant, Freund's 
complete adjuvant. The presence of both IgA and IgG 
anti-OVA antibodies in the sera was then demonstrated 
by an ELISA. An assessment was made of the 
reproducibility of the assay system by performing 
repeated assays on the same serum sample on different 
days. 
2.1.2.Materials and apparatus. 
Freund's complete adjuvant (FCA) - Sigma, Poole, 
Dorset. 
Horse heart myoglobin type III - Sigma. 
Sheep anti-rat IgA horseradish peroxidase conjugate -
Serotec. Oxon. England. 
Sheep anti-rat IgG horseradish peroxidase conjugate -
Serotec. 
Ovalbumin (OVA) - Sigma Grade III. 
Bovine serum albumin (BSA) - Sigma. 
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2,2'-azino-di-(3-ethylbenzthiazoline sulphonate) (ABTS) 
- Amersham, Bucks, UK. 
Microtitre plates PVC - Flow Laboratories, 
Rickmansworth, Herts. 
Titertek Multiskan - Flow Laboratories. 
2.1.3. Methods. 
2.1.3.1. Immunisation protocols. 
(i). SOOpg of myoglobin in O.Sml FCA was injected into 
each of six rats by i.p. injection; sera samples were 
collected 10 days later. 
(ii). S O O ~ g g of ovalbumin in O.Sml FCA was injected into 
each of six rats by i.p. injection and sera samples 
were collected 14 days later. Another 14 days later, 
these rats received a booster dose of 100Vg ovalbumin, 
also in FCA, by i.p. injection; sera were collected 7 
days later. 
2.1.3.2. Immunoassay. 
(a). SOpl of ovalbumin at 1 0 ~ g / m l l in carbonate buffer 
pH 9.S was incubated overnight at 4·C on microtitre 
plate. 
(b). The plate was washed three times in phosphate 
buffered saline pH 7.2 (PBS) containing 0.1% Tween 20. 
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(c). 100pl 1% BSA was added to the plates and incubated 
at room temperature for 30 minutes, then discarded. 
(d). The primary antibody, rat sera or saliva, was 
added at an appropriate dilution and incubated at 37·C 
for 1 hour. 
(e). The plate was washed three times in PBS/O.I% Tween 
20. 
(f). SOpl peroxidase linked second antibody, at 
appropriate dilution, was added and incubated at 37°C 
for two hours. Dilutions of 1/400 for IgA conjugate and 
1/800 for IgG, both in PBS/O.l% Tween 20/1% BSA, were 
found to be appropriate. 
(g). The plate was washed three times in PBS/O.l% Tween 
20. 
(h). 100pi ABTS substrate was added to each well. 
(i). The optical density was read at 40Snm on Titertek 
multiskan 1 hour later. 
2.1.4. Results. 
All ELISA results are quoted as optical density 
values at 40Snm for 1/20 dilutions of sera samples, 
unless otherwise stated. The blank group included in 
table 2.1. received identical treatment to the 
immunised animals, but the irnmunising antigen was 
omitted. In immunisation protocol(ii), the same group 
of animals was repeatedly sampled, including 
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pre-inoculation. This work was performed at Beechams 
Bioscience Research, Epsom, Surrey. 
There was considerable variation in the responses 
from different members of the same group of animals 
(table 2.2). In order to determine if this was due to 
genuine differences in responses from the animals, or 
due to variations in the assay, the same pooled sample 
from immunisation protocol (ii) 35 day collection, was 
repeatedly assayed for both IgA and IgG. The results 
are shown in table 2.3. and showed that the variations 
were due to genuine differences in response from the 
animals. 
In order to determine if values from assays 
performed on different days could be directly compared, 
the same sample from immunisation protocol (ii) 14 day 
collection, was repeatedly assayed for IgG on four 
different days (table 2.4.). 
The results showed that the interday variation was 
such that data obtained from assays performed on 
different days could not be directly compared. 
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Table 2.1. ELISA sera response following 
intraperitoneal injection of myoglobin (mean ±SD n=6). 
IgA 
Blank group o • 1 7 2 ±.O. 0 20 
Immunised group 0.203 iO.005 
IgG 
0.255 ±0.016 
0.669 ±O.342 
Table 2.2. ELISA sera response following 
intraperitoneal injection of ovalbumin (mean ±SD n=5). 
IgA IgG 
Pre-inoculation 0.533 :i0.085 0.927 ±0.094 
14 day 1.065 ±0.429 2.830 ±0.564 
35 day 1.720 .=.0.385 3.154 ±0.502 
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Table 2.3. ELISA sera response following 
intraperitoneal injection of ovalbumin, repeated assay 
of pooled serum sample collected day 35 (mean ±SD n=6). 
Dilution 
1/20 
1/1280 
IgA 
3.166 ±0.033 
1.382 .:1:.0.201 
IgG 
3.345 ±0.012 
3.289 ±0.021 
Table 2.4. ELISA serum response following 
intraperitoneal injection of ovalbumin, repeated assay 
of the same sample on four consecutive days (mean ±SD). 
Number of repeat assays 
per day on same sample. 
4 
4 
2 
2 
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IgG 14 day 
response 
2.249 ±.0.093 
1.258 ±0.120 
1.652 ±O.l02 
1.594 .±O.135 
2.1.5. Discussion. 
In all assays, the sera samples were diluted 
stepwise down the plates, with an initial dilution of 
1/20. For ease of interpretation, normally only the 
results from the initial dilution is quoted, since 
differences between groups are likely to be more 
pronounced at the lowest sample dilution. 
The ELISA system was capable of detecting both IgA 
and IgG rat anti-OVA antibodies in sera following i.p. 
injection of this protein with FCA. The assay appeared 
sensitive, since 35 day sera from immunisation protocol 
(ii) were still "positive n for both IgA and IgG at the 
highest dilution assayed, 1/1280. There did not appear 
to be a great amount of inherent variation in the assay 
when one sample was repeatedly assayed (table 2.3). But 
assays performed on different days were not really 
comparable, since the assay values from the same sample 
varied considerably (table 2.4.). We were advised that 
this was a common problem with ELISA and that 
generally, only samples run in the same assay can be 
compared directly. In most subsequent assays, samples 
from immunisation protocol (ii) 14 day response, were 
used as positive controls. The 35 day response was too 
great, since the Titertek Multiskan shows linearity 
only up to an absorbance value of 2.000. 
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The assay seemed suitable for the attempted 
determination of anti-OVA antibodies in the saliva of 
rats. However, later results brought into question the 
sensitivity of this assay (chapters 4 and 5). 
Therefore, an alternative immunoassay technique, using 
radioisotope labels, was established for the 
determination of rat anti-OVA antibodies. 
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2.2. Radiolabelling with Iodine-125 and 
radioimmunoassay. 
2.2.1. Introduction. 
Two alternative radioimrnunoassays were assessed for 
their potential to measure ovalbumin specific IgA and 
IgG antibodies. The methods utilised Staphylococcus 
aureus Protein A and swine anti-sheep IgG radiolabelled 
with Iodine-l25 as developing reagents. Protein A is 
isolated from certain strains of Staph.aureus; it is a 
cell wall protein that binds selectively to the Fc 
region of immunoglobulin molecules, most notably IgG. 
The reactivity with the Fc region was classified 
originally as a non-specific "pseudo-immune" reaction, 
as opposed to the specific binding of antigen at 
antibody Fab binding sites (120). 
Protein A reactivity is characteristic of IgG from 
most mammalian species, but there is significant 
quantitative differences in the extent of reactivity 
for different species. The extent of reactivity for 
many species has been quantified on the basis of a 
competitive inhibition assay (121). Rat IgG has only 
weak reactivity with Protein A, but the binding of 
sheep IgG is at least 2-3 times better. Although 
relative to some other species, such as human, rabbit 
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or pig, sheep IgG still has quite low reactivity with 
Protein A (122). 
Protein A can in fact display three different types 
of binding activity; (a) the primary reaction with IgG 
and other immunoglobulin classes at sites located in 
the Fc region: (b) a similiar but apparently weaker 
binding located in the Fab region outside the antigen 
binding site: and (c) a typical antigen-antibody 
reaction involving Fab combining sites. For most 
practical purposes, the significant reaction is between 
Protein A and the Fc portion of IgG. Thus Protein A has 
become an extremely important immunochemical reagent 
and has been utilised in a wide range of radio- and 
enzyme- immunoassay procedures, see (121) for review. 
The alternative radioimmunoassay technique involved 
a second anti-antibody, swine anti sheep IgG, which was 
also labelled with lodine-l25. 
2.2.2. Materials and apparatus. 
Staphylococus aureus, protein A - Pharmacia Chemicals 
AB, Uppsala, Sweden. 
Swine anti-sheep IgG - Serotec, Oxford. 
Sheep anti-rat IgG - Serotec. 
Sheep anti-rat IgA - Serotec. 
Iodine-125 (lMS 30) - Amersham International plc, 
Amersham, BUCKS. 
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Chloramine T - Hopkins and Williams, 
Sodium metabisulphite - Fisons, Loughborough. 
Ovalbumin grade III - Sigma Chemicals, Poole, Dorset. 
Bovine serum albumin grade V - Sigma. 
Sephadex G-25, PD-IO column - Pharrnacia. 
Gamma counter - Packard 5610. 
O.5M phosphate buffer - prepared by dissolving 7.1g 
disodium hydrogen orthophosphate (A) and 7.8g sodium 
dihydrogen orthophosphate (B) both in lOOml of 
distilled water. The pH of solution A was then 
monitored as solution B was added dropwise until the pH 
reached 7.5. 
2.2.3. Methods. 
2.2.3.1. Staphylococcus aureus Protein A 
radiolabelling. 
Sodium Iodide-125 was oxidised by the powerful 
oxidising agent chloramine-T to release Iodine-125, 
which was then directly substituted into the aromatic 
ring structures of the protein. 
The purification step, column chromatography, 
cleaned the product of unreacted iodine and some large 
molecular weight aggregates brought about by 
polymerisation. 
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(a). The column was first washed with PBS/Azide 0.02%, 
followed by 5ml 5% BSA and finally with 20ml PBS/Az. 
(b). To the vial in which the IMS 30 was supplied, the 
following were added; 
25pl Staph.Aureus at lmg/ml in 0.5M phosphate 
buffer 
25pl 0.5M phosphate buffer 
25pl Chloramine-T 0.4mg/ml in O.SM phosphate 
buffer 
(c). The reaction mixture was mixed with a pipette tip 
and allowed to stand for 45 seconds. 
(d). The reaction was quenched with l O O ~ l l 0.2mg/ml 
sodium metabisulphite in O.SM phosphate buffer. 
(e). The reaction mixture was then applied to the 
Sephadex PO 10 column along with 2xlOOpl potassium 
iodide 10mg/ml in S%BSA/PBS washings from the reaction 
vial. 
(f). The mixture was eluted with successive volumes of 
O.5m1 PBS and the fractions were collected in tubes 
containing O.Sm1 1% BSA/PBS. 
(g). A 10pl aliquot from each fraction was then counted 
on a gamma counter and the fractions containing the 
peak activity were bulked. 
(h). A 10pl aliquot of the bulked fraction was then 
counted for one minute to determine the activity 
present. The bulked Staph.aureus Iodine-125 solution 
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was then divided into suitable aliquots and stored 
frozen. 
2.2.3.2. Swine anti-sheep IgG radiolabelling. 
The same radiolabelling method was used as described 
for protein A, except the concentration of the protein 
was altered. Swine anti-sheep IgG is supplied at a 
concentration of 9.5mg/ml, but there is likely to be a 
lot of other material present in the sample. Including 
many immunoglobulins directed against totally unrelated 
antigens. Therefore, this product was labelled at a 
concentration of 4mg/ml since the extraneous material 
present in the sample will also be labelled and 
collected. 
2.2.3.3. Radioimmunoassay protocol. 
(a). SOpl of ovalbumin at 1 0 0 ~ g / m l l in PBS/Az, was left 
in wells of microtitre plate overnight at 4·C. 
(b). The plate was washed three times in PBS/O.OS% 
TWeen 20. 
(c). The plate was blocked by 1% BSA 100pi left on 
wells for 30 minutes. 
(d). Serum dilutions in PBS were added to wells and 
incubated overnight at 4°C. 
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(e). The plate was washed three times in PBS/O.OS% 
Tween 20. 
(f). The anti-rat immunoglobulins were added, diluted 
in 1%BSA/PBS/0.OS% Tween 20 at dilutions of 1/400 for 
sheep anti-rat IgA and 1/800 for sheep anti-rat IgG. 
They were incubated for two hours at 37°C. 
Then either step (g)i. or (g)ii. was followed, 
(g)i. SOpl Staph.Aureus Iodine-12S diluted in 1% 
BSA/PBS/O.OS% Tween 20 was added to each well and left 
at room temperature for 3 hours. 
(g)ii. SOpl swine anti-sheep IgG Iodine-12S diluted in 
1% BSA/PBS/0.05% Tween 20 was added to each well and 
left at room temperature for 3 hours. 
(h). The plate was washed three times in PBS/O.OS% 
Tween 20, the individual wells were cut up and put into 
individual tubes and the counts per minute value was 
recorded by the gamma_counter for each tube. 
2.2.3.4. Assessment of radiolabelled reagents. 
The rat sera were diluted across the plate, starting 
at a dilution of 1/2. The assay was run in triplicate 
for both radiolabelled reagents, which allowed a full 
assessment of the suitability of the two reagents for 
the detection of OVA-specific IgA and IgG antibodies. 
Steps (A) to (E), described below, allowed a full 
assessment of the contribution made to the overall 
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result by the non-specific binding of the second 
antibodies to normal rat sera and by the non-specific 
binding of normal sheep sera to "positive" rat sera. 
The "positive" (+ve) rat serum was obtained from an 
animal which had been immunised by sUb-cutaneous 
injection with lOmg ovalbumin in FCA. Serum was 
collected 18 days later. 
(A). OVA + +ve rat serum + sheep anti-rat IgG + 
radiolabel 
(B). OVA + +ve rat serum + normal sheep serum + 
radiolabel 
(C). OVA + normal rat serum + sheep anti-rat IgG + 
radiolabel 
(D). OVA + +ve rat serum + sheep anti-rat IgA + 
radiolabel 
(E). OVA + normal rat serum + sheep anti-rat IgA + 
radiolabel 
2.2.4. Results 
The results from radiolabelling of Staph.Aureus 
Protein A and swine anti-sheep IgG with Iodine-125 are 
shown in tables 2.5. and 2.6. respectively. The total 
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activity present in the radiolabelled products was 
calculated as shown below. 
2.2.4.1. Calculation of total activity present in 
radiolabelled products. 
(i). Staph.Aureus Protein A. 
The peak activity of radiolabelled protein was seen 
in the exclusion volume occuring in fractions 6-8, 
which were bulked. The unreacted iodine-125 started to 
come off the column at fractions 16-18. All the counts 
were taken over 15 seconds. 
Three 20pl aliquots of the pooled fractions 6-8, 
were then counted for 15 seconds. The mean count 
obtained was 1327344. 
The total activity present in the iodinated protein 
sample in pCi was calculated as follows; 
count from bulked fraction x C x FV x (1) x (2). 
E x (2.22 x 106 ) 
where C = figure required to bring counting time to 1 
minute. 
FV = bulked fraction volume in mI. 
(1) = figure to bring the aliquot volume to 1ml. 
(2) = efficiency of the gamma counter 
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2.22 x 106 is a conversion factor to convert from 
counts per minute to pCi. 
Thus total activity present = 4 7 2 ~ C i . .
(ii). Swine anti-sheep IgG. 
The peak activity of radio1abe11ed protein occurred 
in fractions 6-8. Consequently, these samples were 
bulked. All counts were performed over 15 seconds. 
Three 20pl aliquots from pooled fractions 6-8 were 
counted for 15 seconds. The mean count was 1156399. 
The calculation was performed as above. 
Thus total activity present = 411fCi. 
2.2.4.2. Radioimmunoassay. 
The results from the assay involving swine anti-sheep 
125 IgG- I, shown in table 2.8., were relatively easy to 
interpret, with reference to the method described in 
2.2.3.4. The c.p.m. values for the non-specific binding 
of the normal sheep sera to the positive rat sera (B) 
were subtracted from the values for the binding of the 
corresponding dilutions of the second antibodies (A) 
and (0). The values obtained after subtraction were 
then compared to the values obtained for the 
non-specific binding of these same second antibodies at 
the same dilution to a normal (non-immunised) rat sera 
(C) and (E). If these values were significantly greater 
than the corresponding values for (C) and (E), then the 
presence of OVA-specific antibodies would be 
established. 
The results from the assay for OVA-specific IgA 
antibodies involving protein A Iodine-125, shown in 
table 2.7., were also relatively easy to interpret. 
Exactly the same subtractions and comparisons that were 
carried out in the previous situation with swine 
anti-sheep IgG also apply here. However, the results 
for the assay of IgG antibodies using protein A (table 
2.7.) were much more difficult to interpret, since 
protein A binds not only to sheep anti-rat IgG, but 
also to rat IgG. If the second antibody was in excess, 
as it should be at a concentration of 1/800, then all 
the rat IgG should be bound by a second antibody 
molecule. However, the protein A may still bind to the 
rat IgG, since it may interact at a completely 
different combining site which may still be exposed. 
Therefore, it is possible that the two reagents will 
interact to amplify the result obtained for IgG. 
Despite the complexities of interpretation, the assay 
for OVA-specific IgG using protein A was still valid, 
Qlthough the subtractions described earlier were no 
longer necessary. The values obtained from positive and 
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normal sera were compared directly while ensuring that 
the corresponding values from normal sheep sera were 
not unreasonably high. 
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Table 2.5. Counts per minute for different fractions of 
Iodine-125 labelled Staphylococcus aureus Protein A. 
Fraction number. Count. 
1 17 
2 26 
3 19 
4 17 
5 221 
6 201443 
7 1955577 
8 639990 
9 64332 
10 19412 
11 11327 
12 11704 
13 12315 
14 13227 
15 16750 
16 26051 
17 82301 
18 113701 
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Table 2.6. Counts per minute for different fractions of 
Iodine-125 labelled swine anti-sheep IgG. 
Fraction number Count 
1 11 
2 10 
3 19 
4 13 
5 17 
6 72471 
7 1039865 
8 413591 
9 46189 
10 18049 
11 27190 
12 19180 
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(A). OVA + +ve rat serum + sheep anti-rat IgG + 
radiolabel 
(B). OVA + +ve rat serum + normal sheep serum + 
radiolabel 
(e). OVA + normal rat serum + sheep anti-rat IgG + 
radiolabel 
(D). OVA + +ve rat serum + sheep anti-rat IgA + 
radiolabel 
(E). OVA + normal rat serum + sheep anti-rat IgA + 
radiolabel 
Table 2.7. Radioimmunoassay results for Iodine-125 
labelled Staphylococcus aureus Protein A, counts per 
minute (mean n=3). 
See method 2.2.3.4. for full description of (A) to (E). 
(A) • (B) • (C) • (D) • ( E) • 
DILUTION 
1/2 140125 29902 6692 134071 1743 
1/4 103119 29511 7077 110179 2020 
1/8 86432 30603 7158 78772 2319 
1/16 65453 28936 5933 55837 2228 
1/32 47633 25332 5236 42241 1686 
1/64 33961 21077 4847 32510 1436 
1/128 29295 17559 3827 26275 1344 
1/256 27222 13452 3622 19360 2126 
1/512 23853 9748 5114 15741 2495 
1/1024 19587 7667 3558 10366 2359 
1/2048 15608 5807 2788 7950 2180 
1/4096 12872 4226 3219 5258 1496 
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Table 2.8. Radioimmunoassay results for Iodine-125 
labelled swine anti-sheep IgG, counts per minute (mean 
n=3) • 
See method 2.2.3.4. for full description of (A) to ( E) • 
(A) • (B) • (C) • ( D) • ( E ) • 
DILUTION 
1/2 12115 3287 11649 7054 6134 
1/4 11412 2941 11500 9338 5579 
1/8 11925 4240 10913 10805 4809 
1/16 16118 5371 8381 8113 4568 
1/32 18414 3881 6306 10034 4708 
1/64 14392 6653 8030 7749 5133 
1/128 15680 2256 2694 6037 4994 
1/256 14590 4487 3267 7471 4396 
1/512 14814 2719 3154 4996 2166 
1/1024 13058 2714 3849 5974 4904 
1/2048 14316 3124 3217 3941 3697 
1/4096 8785 3295 2783 1565 3017 
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2.2.5. Discussion. 
The assay method 2.2.3.4. allowed a full assessment 
of the effects of non-specific binding of the second 
antibodies to normal rat sera and of normal sheep serum 
to "positive" rat sera. Although normal sheep serum 
will not be identical to the material present in the 
highly processed second antibodies, it was thought that 
an assessment of the non-specific binding capacity of 
this reaqent was necessary. The incorporation of normal 
sheep serum into the assay was the nearest 
approximation that could be achieved, since the precise 
processing of the second antibodies was unknown. 
With radiolabelled swine anti-sheep IgG, the presence 
of OVA specific IgG antibodies in the "positive" rat 
sera was indicated. However, this particular assay 
system did not demonstrate the presence of OVA specific 
IgA antibodies. 
With radiolabelled Protein A, satisfactory results 
were obtained, since both OVA specific rat IgA and IgG 
antibodies were detected. Non-specific binding was low 
throughout, both for the binding of the second antibody 
to the normal rat sera, and for normal sheep to 
"positive" rat sera. Therefore, the assay system 
involving radiolabelled Protein A was selected for 
further work. 
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2.3. polyacrylamide gel electrophoresis. 
2.3.1. Introduction 
In order to demonstrate that the antigenicity of 
ovalbumin was unchanged by the adsorption to poly 
2-butyl cyanoacrylate (p(BCA» particles, or by the 
entrapment within liposomes, antibody responses to the 
formulated antigen should be assessed by assay against 
the native antigen. However, by performing 
polyacrylamide gel electrophoresis (PAGE) on the 
solubilised formulated antigen and imrnunoblotting 
against native OVA specific antibody, it is possible to 
determine whether the formulated antigen does have 
retained antigenic determinants. 
Sodium dodecyl sulphate (SDS) PAGE is one of the 
most widely used methods for separating protein 
mixtures and for determining their molecular weight. 
SDS is an anionic detergent which causes denaturation 
and solubilisation of proteins. The efficiency of the 
solubilisation is due to the mutual electrostatic 
repulsion of the protein following the binding of a 
large number of detergent molecules on the surface. 
Proteins assume a rod shaped structure and the 
migration velocity shows an inverse linear correlation 
with the logarithm of the protein molecular weight. 
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Therefore, formulated ovalbumin was solubilized with 
50S, electrophoresed on polyacrylamide gels and then 
blotted onto a nitrocellulose membrane (NC). The NC was 
incubated with rat sera containing OVA specific 
antibodies, prior to being probed with an anti-rat IgG 
horse radish peroxidase conjugate. Successful 
development of the immunoblot would confirm that 
anti-OVA antibodies in the rat sera still bound to 
formulated OVA. 
Gels are produced when the acrylamide monomer is 
copolymerised with a cross-linking agent, usually 
N,N'-methylenebisacrylamide, in the presence of a 
catalyst accelerator chain-initiator mixture. This 
mixture will usually consist of freshly prepared 
ammonium persulphate as catalyst, together with 
N,N,N',N'-tetramethylenediamine (TEMED) as initiator. 
The porosity of a gel is determined by the relative 
amounts of acrylamide monomer and cross-linking agent 
used. The lower the percentage of acrylamide used, the 
larger the pore size present and so the lesser the 
resistance to the passage of large molecules. 
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2.3.2. Materials and apparatus. 
Acrylamide, bisacrylamide and ammonium persulphate -
Bio-rad electrophoresis purity reagent, Bio-rad Labs, 
Richmond, California, U.S.A. 
Sodium dodecyl sulphate - 'specially pure', BOH 
chemicals Ltd, Poole, England. 
Tween 20 - Sigma Chemicals, Poole, England. 
Trizma base- Sigma. 
Bromophenol blue - BOH. 
Mercaptoethanol - BOH 
Glycine - BOH. 
Coomassie brilliant blue R - Sigma. 
Ponceau S - Sigma. 
Ovalbumin - Grade III, Sigma. 
Mini protean II cell - Bio-rad. 
Power supply EPS 500/400 - Pharmacia AB, Uppsala, 
Sweden. 
50S reducing buffer consisting of; 
distilled water 
0.5M Tris-HCl pH 6.8 
glycerol 
10% (w/v) SOS 
4.0ml 
1.0ml 
0.8ml 
1.6ml 
2-mercaptoethanol 0.4ml 
0.05% (w/v) bromophenol blue 0.2ml 
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Running buffer pH 8.3 consisting of; 
Tris base 0.3% 
glycine 1.2% 
SDS 0.1% 
2.3.3. Method. 
A discontinuous gel was cast consisting of a stacking 
upper gel (4% acrylamide) and a resolving lower gel 
(10% acry1amide). The stacking gel acts to concentrate 
the samples and so results in better resolution in the 
resolving gel. During the casting of the stacking gel, 
a ten wedge comb produced the wells into which the 
samples were introduced. 
The following samples were electrophoresed after 
solubi1isation in SOS according to the method of 
Williams et a1 (123): 
(1). Native OVA solution. 
(2). OVA encapsulated in liposomes. 
(3). OVA adsorbed to p(BCA) particles stabilised with 
dextran 70. 
(4). OVA adsorbed to p(BCA) particles stabilised with 
B-cyc10dextrin. 
Samples (3) and (4) were prepared as described in 
6.3.1. and isolated by centrifugation. Unbound OVA was 
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washed off and the particles were resuspended in PBS 
and stirred at room temperature overnight. The 
liposomes were prepared as described in 4.3.1. 
Aliquots of samples (1) - (4) were mixed with an 
equal volume of reducing buffer and heated at 100°C for 
ten minutes. Twenty microlitres of each cooled sample 
was introduced into the sample wells using a Hamilton 
pipette. This was performed in duplicate in two gels. 
The cell was then run at 200V for about 45 minutes. 
The gel was removed from the cell and placed in 
Coomasie brilliant blue stain for 30 minutes, then left 
in de-stain (40% methanol, 10% acetic acid) overnight. 
2.3.4. Results. 
A photograph of a typical polyacrylamide gel is shown 
in figure 2.1. 
2.3.5. Discussion. 
The major protein components of the four OVA samples 
described in the methods, 2.3.3., were electrophoresed 
to the same level in the gel, indicating that ovalbumin 
had not been degraded during its incorporation into 
liposomes or its adsorption to p(BCA) particles. 
The proteins were blotted from the gel to a 
nitrocellulose membrane so that they could be probed 
immunologically. 
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(1) (3) 
Figure 2.1. Sodium dodecy1 sulphate polyacrylamide gel 
electrophoresis of (1) native ovalbumin, (2) ovalbumin 
incorporated in liposomes and ovalbumin adsorbed to (3) 
beta-cyclodextrin and (4) dextran 70 stabilised poly 
2-butylcyanoacrylate particles. 
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2.4. Immunoblotting. 
2.4.1. Introduction. 
This section describes the blotting of ovalbumin 
from acrylamide gel to a nitrocellulose membrane and 
its immunological probing. Successful development of 
the immunoblot would confirm that the immune response 
to formulated ovalbumin can be assessed by immunoassay 
techniques which involve initial binding to the native 
antigen. 
After separation of proteins in a gel matrix, 
staining is often limited by properties of the matrix 
itself. Thickness and non-uniformity affect the 
permeability to stains, while difficulty in handling 
and limits in durability restrict the use of multiple 
consecutive stains. These limitations are all lessened 
by the electrotransfer of proteins from the gel to a 
thin matrix, most commonly nitrocellulose paper. This 
is known as electroblotting or 'western blotting' and 
under optimal conditions over 90% of the protein is 
transferred. 
For detection of proteins on nitrocellulose, the 
double antibody enzyme immunoassay system using 
horseradish peroxidase and 4-chloro-1-naphthol is 
generally recommended over all other systems because of 
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good sensitivity and negligible background development 
(Bio-rad technical literature). 
The PAGE procedure as described in 2.3.3. was 
repeated, but the ovalbumin was not stained with 
coomassie blue, it was transferred to a nitrocellulose 
membrane. 
2.4.2. Materials and apparatus. 
PAGE - see section 2.3.2. 
Sheep anti-rat IgG peroxidase conjugate - Serotec, 
axon. 
4-chloro-1-naphtho1 - Sigma Chemical co., Poole, 
Dorset. 
Trans blot cell - Bio-rad Labs, Richmond, California, 
U.S.A. 
Nitrocellulose membrane - Bio-rad. 
Power supply model 3000/300 - Bio-rad. 
2.4.3. Methods. 
2.4.3.1. Electrotransfer. 
OVA was transferred from the gels by electroblotting 
according to the method of Towbin et al (124) and was 
detected by immunoblotting. The cell was run at 60V for 
about 5 hours, immersed in ice throughout to keep it 
cool. 
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The presence of the transferred protein was 
demonstrated with the reversible stain ponceau red, 
which was then washed off. 
2.4.3.1. Immunological detection. 
(a). The blot was soaked in 0.3% Tween 20 in 
saline/tris buffer (0.9% NaCl, 10mM tris HCl pH 7.4) 
for 1 hour at room temperature. 
(b). It was then incubated with the first antibody, rat 
sera containing anti-OVA antibodies (positive control 
5.5.1.), diluted 1/50 in 0.3\ Tween 20/saline/tris for 
4 hours at room temperature. 
(c). It was then washed six times in tris/saline and 
incubated with the second antibody, sheep anti-rat IgG 
peroxidase conjugate, diluted at 1/1000 in 0.3% Tween 
20/saline/tris for 2 hours at room temperature. 
(d). It was then rinsed six times in saline/tris. 
(e). The blots were then soaked in a solution of 25pg 
of 4-chloro-1-naphthol per ml in 0.01\ hydrogen 
peroxide /lOmM tris HCl pH 7.4. This solution was 
prepared fresh, with 4-chloro-l-naphthol being first 
dissolved in a small amount of methanol and then added 
to the solution containing the peroxide and tris. 
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(f). The reaction was terminated after about thirty 
minutes by washing the blot with distilled water.The 
blots were then photographed. 
2.4.4. Results. 
See section 2.3.4. for a photograph of a typical 
polyacrylamide gel. A photograph of the developed 
immunoblot is shown in figure 2.2. 
2.4.5. Discussion. 
Antibodies raised against native ovalbumin still 
combined with ovalbumin following incorporation into 
liposomes or adsorption to poly (2-butylcyanoacrylate) 
particles. Therefore the immune response to formulated 
ovalbumin can be reliably assessed by standard 
immunoassay techniques which involved initial binding 
to the native antigeneg. ELISA and RIA. 
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0) (2) (3) (4) 
Figure 2.2. Developed immunoblot of ovalbumin samples 
(1) - (4) described in legend for Figure 2.1. after 
their electrotransfer to a nitrocellulose membrane. 
-86-
2.5. Lowry assay. 
2.5.1. Introduction. 
Due to its simplicity, sensitivity and precision, 
the method of Lowry et al (125) is the most widely used 
assay for the quantitative determination of proteins. 
The method is based on the Fo1in-Cioca1teau phenol 
reagent, in which the active constituent is 
phosphomo1ybdic-tungstic mixed acid. Proteins cause a 
reduction of the mixed acid and produce one or more of 
several possible reduced species which have a 
characteristic blue colour. Copper apparently chelates 
in the peptide structure and facilitates electron 
transfer, thereby increasing sensitivity to protein. 
The principle chromogenic amino acids are tryptophan 
and tyrosine. Various modifications of this assay have 
been suggested (126). A modification which showed a 
more linear photometric response was employed in this 
work (127). 
2.5.2. Materials and apparatus. 
Fo1in-Cioca1teaus phenol reagent -Sigma. 
Potassium sodium tartrate - BOH. 
Sodium carbonate - BDH. 
Copper sulphate - Sigma. 
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Kontron uvikon 860 Spectrophotometer. 
2.5.3. Method. 
solution A - 2g potassium sodium tartrate and 100g 
sodium carbonate were dissolved in 500ml 1M NaOH and 
diluted with water to lL. 
Solution B - 2g potassium sodium tartrate and 19 copper 
sulphate wre dissolved in 90ml of water and 10ml of 1M 
NaOH was added. 
Solution C - (prepared daily) 1 volume 
Folin-Ciocalteaus reagent was diluted with 15 volumes 
of water. 
Iml of the protein sample was treated with O.9ml 
solution A in a test tube and placed in a water bath at 
50·C for 10 minutes, then cooled to room temperature. 
It was then treated with O.lml solution B and left at 
room temperature for 10 minutes before 3ml solution C 
was added rapidly and mixed on a vortex within 1 
second. The tubes were again heated at 50°C for 10 
minutes and cooled to room temperature. The absorbances 
were read in a lcm cuvette at 650nm. 
Unknown protein samples were compared with a set of 
standards run concurrently in the assay. 
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2.5.4. Results. 
To validate and characterise the assay, the same six 
standard solutions of ovalbumin were assayed on six 
separate days (table 2.9.). 
2.5.5. Discussion. 
The literature indicates that the Lowry assay is 
/ 
sensitive to the determination of proteins as low as 
5pg (126). In our hands, the assay was sensitive to 
the determination of 25pg ovalbumin, lower amounts were 
not attempted since this was not required. However, 
variation in the absorbance values occurred when the 
same standards were assayed on different days. For the 
lower amounts of ovalbumin assayed, the standard 
deviations of the mean were about 10%, or more, of the 
total amount of ovalbumin present. This was considered 
to be an unacceptable degree of day to day variation in 
the assay. Therefore, when the assay was used 
subsequently, a set of standards were always run in the 
assay alongside the unknown samples for a direct 
comparison. The assay proved sensitive and precise for 
the accurate determination of ovalbumin, whenever 
required. 
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Table 2.9. Reproducibility of the Lowry assay (mean ±SD 
n=6) • 
Values quoted are absorbances at 650nm. 
OVA ()lg) 25 50 100 150 200 250 
assay 
number. 
1. 0.092 0.151 0.300 0.420 0.585 0.688 
2. 0.120 0.182 0.331 0.504 0.608 0.672 
3. 0.120 0.188 0.342 0.479 0.650 0.729 
4. 0.112 0.195 0.388 0.555 0.688 0.785 
5. 0.100 0.192 0.327 0.511 0.637 0.721 
6. 0.120 0.242 0.379 0.496 0.686 0.768 
mean 0.111 0.192 0.345 0.494 0.642 0.727 
±SD ±0.012 ±0.029 ±0.033 ±0.044 ±0.041 ±0.044 
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2.6. Amino acid analysis. 
An automatic amino acid analysis technique was 
required to determine the extent of entrapment of 
ovalbumin in polyacrylamide micropartic1es, because 
extensive hydrolysis of the particles was required to 
release the entrapped protein. This work was kindly 
performed on our behalf at Beechams Biosciences 
Research Division, Epsom, using the Waters PICO-TAG 
system. Three main steps were involved: 
(1). Hydrolysis of the protein to yield free amino 
acids, 
(2). Pre-column derivatization of the sample 
(Figure 2.3.) 
(3). Analysis by reverse phase HPLC. 
In the pre-column steps, protein samples were first 
hydrolysed with HCI, then derivatized with 
phenylisothiocyanate to produce phenylthiocarbamyl 
amino acids. These amino acid derivatives may then be 
analysed by HPLC in amounts as low as 1 picomo1e. 
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Figure 2.3. Phenylisothiocyanate derivatization of 
amino acids to produce phenylthiocarbamyl amino acids 
for analysis by high performance liquid chromatography. 
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3. IMMUNISATION PROTOCOLS. 
3.1. Introduction. 
A wide range of immune reactions may be elicited 
following oral immunization involving both the 
secretory and the systemic immune systems. The response 
to oral immunization seems to depend on a number of 
variables such as antigen type, dose, frequency of 
exposure and prior immune status of the individual. 
Other factors such as species, strain and age on 
exposure will also playa part. 
Oral immunisation may give rise to antibodies, mainly 
IgA, in the gastrointestinal tract (128) and at distant 
sites such as mammary glands (129), lacrimal glands 
(130), or salivary glands (131). This occurs via the 
"common enteromucosal secretory antibody system". 
Enteric administration of antigens to unprimed animals 
can blunt the immune response to subsequent parenteral 
challenge with that same antigen, i.e. systemic 
tolerance (128,132-136) (Figure 3.1.). Such systemic 
hyporesponsiveness is antigen specific and will not 
develop if the animal has received prior systemic 
exposure to the antigen. Systemic tolerance appears to 
be induced via a suppressor circuit initiated in the 
gut associated lymphoid tissue upon exposure to 
antigen. A T suppressor-inducer cell (Tsi) resides in 
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Figure 3.1. - A simplified flow diagram illustrating 
the simultaneous processes of systemic tolerance and 
local antibody production. Antigens enter through the M 
cells and interact with the B lymphocytes to produce 
primed B lymphocytes (BAprimed) which then pass through 
the mesenteric lymph nodes (M.L.N.) and seed out to all 
secretory sites where they produce antibody. T helper 
cells (Th ) interact with the B lymphocytes and assist 
the priming process. T switch cells (T .) also present SWl 
in the Peyer's Patches isotype switch the B lymphocytes 
so that most produce 19A. Following exposure to antigen 
T suppressor inducer cells (Tsi ) within the gut 
lymphoid tissue migrate to the spleen and interact with 
certain splenic cells to produce effector T suppressor 
cells (T ). T inhibit the production of 19G and 
sup sup 
19M from the respective plasma cells (BG and BM) 
resulting in systemic tolerance. Tsi within the Peyer's 
Patches prevent terminal maturation of the lymphocytes 
within the lymphoid follicles. 
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Figure 3.1. A simplified flow diagram illustrating the 
production of systemic tolerance at the same time as 
local antibody production. 
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the lymphoid tissue and can migrate to the spleen after 
exposure to antigen. In the spleen the Tsi cells 
interact with specific splenic cells to produce an 
effector T suppressor cell (Tsup) (137). The 
simultaneous production of IgA T helper and 19M and IgG 
T suppressor cells has been demonstrated in Peyer's 
Patches cells in vitro (138) and in vivo (139). Such 
results help to explain how a very good local antibody 
response can occur at the site of penetration at the 
same time that suppressor cells are being induced. The 
Tsi cells have no suppressive capacity on their own in 
the absence of splenic cells. However, this is by no 
means the complete picture; suppression has been 
ascribed by some workers to soluble serum factors 
(140,141) and there have been reports of distinct T 
cell derived soluble suppressors (142). It has been 
reported that suppressor cells disappear from the 
spleen and the thymus after cell transfer experiments 
well before the disappearance of tolerance (143). The 
tolerogenic effect of ovalbumin has been investigated 
in mice. On absorption across the gut the ovalbumin is 
subtly altered into a tolerogenic form which is likely 
to exert its tolerogenic effect by activating 
suppressor T cells (144,145). 
The simultaneous production of secretory antibodies 
and systemic tolerance (146), or enhanced antigen 
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exclusion at the same time as systemic tolerance (147) 
has been observed. It has also been shown that oral 
immunization with bacteria may give rise to salivary 
antibodies and systemic priming rather than tolerance 
(148). The induction of tolerance to orally 
administered antigen has been shown to be time and dose 
dependent (149). 
Serum responses to orally administered soluble 
antigens have been reported in some species (150,151), 
though no serum antibody response was reported in mice 
after oral administration of ovalbumin (146). However, 
a serum antibody response to ovalbumin in mice was 
reported following a different feeding regimen (149). A 
small serum response to a single gastric intubation of 
bovine serum albumin has been reported in Osborn Mendel 
rats (28) and a small serum response to both repeated 
gastric and repeated oral administration has been 
reported in Wistar rats {152,153). The differing 
responses of different species to an identical feeding 
regimen has been highlighted in one study (154). All 
species studied showed similiar levels of circulating 
antigen, but infants and rabbits showed a serum immune 
response to BSA which was dose dependent, whilst rats 
and mice displayed systemic tolerance (154). The work 
quoted on serum responses to oral administration was 
carried out in unprimed animals, it is important to 
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note that the prior immunologic status of the animal 
determines the effect of subsequent feeding. If a 
soluble antigen is first administered parenterally, 
subsequent feedings either fail to induce tolerance, or 
may actually boost antibody titers, this depends on the 
site of injection (ISS). 
It seems that gut immune responses are neither wholly 
negative nor wholly positive, but are the result of 
delicate balances between opposing forces. No general 
rules apply which allow the accurate prediction of the 
outcome of oral administration. Though it seems likely 
that the site of antigen uptake in the gut will 
influence to a great extent the response induced, if 
any. Physiologically, it is likely that the main role 
of intestinal IgA is to reduce the absorption of 
antigens across the gut, that is immune exclusion. The 
role of systemic tolerance is likely to be defensive 
also, it may act to prevent the development of certain 
hypersensitivity and auto-immune diseases by preventing 
damaging immune reactions to antigens that have escaped 
immune exclusion. 
The first objective relating to animal work in this 
study was to generate a significant positive salivary 
immune response to a soluble antigen and to demonstrate 
that this could be detected by an ELISA. It has been 
reported that salivary immune responses to DNP 
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haptenated species are relatively easy to induce by 
salivary gland vicinity (SGV) injection alone, or by a 
combination of mucosal site injection and oral 
administration (157-159). Therefore, two protein 
carriers, MYO and BGG, were haptenated with DNP and 
used as immunising agents in experiments involving SGV 
injection. However, most studies that have successfully 
induced a salivary response have used long term feeding 
of antigen or non-viable bacteria. Salivary responses 
have been shown to be generally short lived 
(130,131,148), suggesting that after migration of 
antigen sensitive cells from Peyer's Patches to 
salivary glands, cells do not continue to secrete 
antibodies in the absence of any local challenge. It 
has been demonstrated that a reproducible salivary 
immune response is difficult to achieve and depends to 
a great extent on the immunization protocol used (148). 
It was shown that repeated gastric intubation (g.i.) of 
an antigen over at least three days is required to 
induce a reproducible and significant positive salivary 
immune response in mice (148). The response to repeated 
g.i. has been confirmed in the rat. It has also been 
shown that a much better salivary response is achieved 
if a booster dose of antigen is administered by g.i. 
more than two months after the original exposure (25). 
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The ELISA technique had been validated for the 
determination of OVA-specific rat IgA and IgG 
antibodies in the sera following i.p. injection 
(chapter 2). We now hoped to extend this work to the 
determination of anti-OVA IgA and IgG antibodies in rat 
saliva. Therefore, a series of immunisation protocols 
was undertaken in the attempt to induce a significant 
positive salivary immune response. After the 
establishment of a reliable immunisation protocol, we 
could then attempt to enhance the salivary response by 
association of the model protein with the chosen 
colloidal carriers. 
In all experiments, involving g.i. of antigen, 
saliva was collected two weeks after the first dose of 
the daily repeated gastric intubation regime. Since 
salivary antibody levels are generally accepted as 
peaking at about this time (95,145,159). 
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3.2. Materials and apparatus. 
Male wistar rats 200g were used throughout. 
Pentobarbitone sodium 60mg/ml - 'Sagatal' M & B 
veterinary, Dagenham, Kent. 
Halothane - ICI pIc, Macclesfield, Cheshire. 
pilocarpine 1% eye drops - Kirby Warrick, Mildenhall, 
Suffolk. 
Horse heart myoglobin type III (MYO) - Sigma chemicals, 
Poole, Dorset. 
Bovine gamma globulin fraction II (BGG) - Sigma. 
Ovalbumin grade III - Sigma. 
Freunds adjuvant, complete - Sigma. 
2,4,-Dinitrobenzene sulphonate (DNP) - K & K labs, 
Hollywood, California. 
Sodium carbonate - BDH chemicals, Poole, Dorset. 
Micro-haematocrit centrifuge - Hawksley and Sons Ltd, 
Lancing, Sussex. 
Micro-haematocrit capillary tubes, plain and 
heparinised - Hawksley and Sons Ltd. 
Micro eppendorf tubes, SOOpl - Sarstedt, west Germany. 
Oral dosing needles - made from a curved syringe needle 
(size 199 x 2") with a smoothed rounded piece of silver 
solder on the end. 
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Anaesthetic apparatus - Fluotec, Cyprane Ltd., 
Keighley. 
3.3. Methods. 
3.3.1. Gastric intubation. 
The solution was administered into the stomach 
via a dosing needle inserted down the oesophagus. 
3.3.2. Saliva collection. 
Animals were anaesthetized with i.p. 
pentobarbitone O.lml/lOOg or by inhalation of 
halothane 2%. Saliva was stimulated by the i.p. 
injection of pilocarpine 0.1ml/100g, lmg/ml and was 
collected into plain capillary tubes from the corner of 
the mouth as the animal was laid on its back, slightly 
tilted to the collection side. 
3.3.3. Sera collection. 
In earlier terminal experiments, blood samples 
were taken by cardiac puncture from pentobarbitone 
anaesthetized animals. However, in later work, when 
recovery experiments were performed, blood was 
collected by serial sampling from the tailtip into 
heparinised capillary tubes from halothane 
anaesthetized animals. The capillary tubes were then 
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sealed in a bunsen flame and the sera was collected by 
spinning down the blood in a capillary centrifuge. 
3.3.4. 2,4,-Oinitrophenol haptenation. 
One gram of the protein to be haptenated and 19 of 
potassium carbonate were dissolved in 50ml of water, 19 
of dinitrobenzene sulphonate was added and the mixture 
was stirred gently at room temperature for 18 hours in 
a conical flask surrounded by aluminium foil. The 
mixture was then dialysed against running tap water at 
4°C for 48 hours. Dialysis was then continued against 
distilled water for two days with six changes of water 
(method supplied by Beechams). 
3.3.5. Immunisation protocols. 
3.3.5.1. Salivary gland vicinity injections. 
(i). 2 x lml of O.Sml MYO/ONP 500pg/ml and O.5ml FeA 
was injected subcutaneously at the sites of the 
salivary glands in four rats, saliva was collected ten 
days later. 
(ii). 4 x 0.2ml of O.lm1 BGG/ONP 2mg/m1 and 0.lm1 FCA 
was injected subcutaneously at each of the four main 
salivary glands, saliva was collected ten days later. 
3.3.5.2. Salivary gland vicinity injection and gastric 
intubation. 
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Initially, 2 0 0 ~ g g BGG/DNP was gastrically intubated in 
200pl PBS into six rats. Ten days later, 200pg BGG/DNP 
in 200pl FCA was injected subcutaneously into each rat 
at the salivary glands. Seven days later, the SGV 
injection was repeated, saliva was collected five days 
later. 
3.3.5.3. Repeated gastric intubation of myoglobin. 
(i). 200pg MYO in 200pl PBS was intubated gastrically 
on four consecutive days to six rats, saliva was 
collected fourteen days after the initial intubation. 
(ii). 200pg MYO in 200p1 PBS was intubated gastrically 
on four consecutive days to six rats. The animals were 
then left untreated for more than two months. A further 
dose of 200P9 MYO in 200p1 PBS was then intubated 
gastrically, saliva was collected two days later. This 
long term boosted response is termed the "memory" 
response. 
3.3.5.4. Repeated gastric intubation of ovalbumin. 
One milligram of ovalbumin in 2S0p1 PBS was 
gastrically intubated on four consecutive days to six 
rats, saliva was collected fourteen days after the 
initial intubation. 
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For all immunisation protocols, the group mean ELISA 
saliva results from the immunised animals was compared, 
in an unpaired Students "t" test, with the results for 
blank saliva collected from animals which had received 
identical treatment, but the immunising antigen had 
been omitted. All ELISA values are quoted as optical 
density readings at 405nm; only the values from the 
lowest dilutions of saliva assayed are shown. The group 
mean values are considered to be statistically 
significant if in the "t" test, p < 0.05, an * 
indicates when this is so. 
3.4. Results. 
3.4.1. Salivary gland vicinity injections. 
Detectable salivary immune responses could not be 
detected from any of the animals immunised by SGV 
injection alone, or by combined g.i. and SGV of 
BGG/DNP. None of the values obtained from the immunised 
animals differed from the values obtained from the 
blank groups. Table 3.1. shows the results from a 
typical assay for IgA in saliva. Many other similiar 
assays were performed, with slightly different assay 
conditions in each case, but all proved negative for 
both IgA and IgG. Since in all cases these results were 
negative they have not been shown. Because of the 
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failure of these immunisation protocols, in subsequent 
experiments, the model antigens were administered by 
repeated g.i. 
3.4.2. Repeated gastric intubation of myoglobin. 
The salivary immune response to repeated gastric 
intubation of myoglobin is shown in table 3.2. This 
table also shows the salivary memory response to 
myoglobin, though these results were obtained from a 
different group of experimental animals. 
The repeated g.i. of MYO at 2 0 0 ~ g g per day for four 
days did not induce a significant positive salivary 
response. However, when a booster dose of MYO was given 
by g.i. more than two months later, a significant 
positive salivary IgA response was elicited 
(significant at p < 0.01 when compared with 'blank' 
saliva in Unpaired Student Wt W test). 
3.4.3. Repeated gastric intubation of ovalbumin. 
The salivary immune response to the repeated gastric 
intubation of ovalbumin is shown in table 3.3. The 
repeated g.l. of OVA at lmg per day for four days 
induced a significant positive salivary IgA response 
(significant at p < 0.02 when compared with 'blank' 
saliva in Unpaired Student Wt" test). 
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Table 3.1. ELISA saliva response following gastric 
intubation, followed by repeated salivary gland 
vicinity injection of BGG/DNP (mean ±SD n=6). 
IgA 
Blank group 0.130 ±0.010 
Immunised group 0.133 ±0.005 
Saliva samples diluted l/S in PBS. 
Table 3.2. ELISA salivary response following repeated 
gastric intubation of myoglobin (mean ±SD n=6). 
Blank group 
2 0 0 ~ 9 9 x 4 repeated 
Blank group 
Memory group 
IgA 
0.490 .±0.OS7 
0.539 ±0.047 
IgG 
0.786 ±-0.055 
0.704 ±0.104 
Memory saliva response. 
0.675 ,±0.100 0.327 ±0.010 
1.429 +0.427 " 0.388 .:1:0.048 
All saliva samples diluted 1/5 in l%BSA/PBS. 
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Table 3.3. ELISA salivary response following repeated 
gastric intubation of ovalbumin (mean ±SD n=6). 
Blank saliva 
Img x 4 repeated 
IgA 
0.615 
0.640 
0.969 ±0.124 * 
IgG 
0.335 
0.311 
0.322 ±0.009 
Saliva samples diluted 1/10 in l%BSA/PBS, only two 
blank samples were run in this assay. 
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3.6. Discussion. 
The objective of this work was to establish an 
immunisation protocol which would induce a significant 
positive salivary immune response in the Wistar rat. 
Salivary gland vicinity injections alone, or in 
combination with gastric intubation, with a 
DNP-haptenated protein did not generate a significant 
positive salivary antibody response. Most researchers 
have reported that salivary immune responses are 
generally very difficult to achieve and this perhaps is 
not particularly surprising since the normal 
physiological response following absorption of antigen 
across the gut is likely to be tolerance. A failure in 
this protective mechanism may lead to damaging 
consequences for the individual. Challacombe has shown 
that in mice, repeated oral administration of antigen 
over at least three days is required (148). Me has also 
reported that SGV injections are not a very reliable 
method of inducing a positive salivary immune response 
in rats (personal communication). The work published 
supporting the use of SGV did not offer any explanation 
as to why this route of administration of antigen 
should be any better than a simple sub-cutaneous 
injection of antigen. In retrospect, it must be 
concluded that SGV injection was not a very good 
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immunisation protocol to select. Also, the ELISA 
technique for the determination of DNP-specific 
antibodies was hampered by the release of unreacted DNP 
from the conjugate in solution. This problem is likely 
to result in reduced sensitivity of the assay, since 
DNP-specific antibodies may bind to a group that is 
subsequently lost into solution as the assay 
progresses. Therefore, it was obvious that the dialysis 
technique described in section 3.3.4., was not 
effective at removing all unreacted DNP from the 
conjugate. This problem could have been resolved by 
removing the unreacted DNP by column chromatography, 
but this did not prove necessary as the DNP-haptenated 
species were replaced by native protein models for oral 
administration studies. The use of native protein 
antigens allowed us to demonstrate that there was no 
major structural or conformational changes in the 
protein during its incorporation into, or adsorption 
onto, the colloidal carriers (see section 2.3.). If the 
DNP-haptenated species was used, the proteins may have 
been extensively degraded, but we may still detect 
immune responses to the DNP hapten on protein 
fragments. We are interested in immune responses to an 
intact protein following its oral administration. 
Significant positive salivary immune responses were 
induced following gastric intubation alone. The 
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boosted, or -memory" immune response was considerably 
greater than the primary immune response, with 
myoglobin, but this response was generated after a 
delay of more than two months. This made the experiment 
very time consuming and expensive, since the 
experimental animals needed to be kept over an extended 
period. 
positive immune responses were detected in saliva 
that was not processed in any way prior to freezing. 
There had been some worry that the various substances 
present in saliva, mucins, food, enzymes etc. might 
inactivate or denature the antibodies, but this did not 
prove to be so. Although, there is a possibility that 
the detected responses may have been considerably 
greater if some processing step eg. enzyme inhibition, 
or removal of particulates, had been undertaken. 
It was decided that the results obtained from the 
immunisation protocols undertaken justified moving onto 
the next stage of the project, the incorporation of 
ovalbumin into colloidal carriers and the assessment of 
the immune responses following gastric intubation of 
these carriers. 
An immunisation protocol involving the repeated 
gastric intubation of Img ovalbumin per day, for four 
days, was selected to be used in subsequent studies. In 
later work, when recovery experiments were allowed, the 
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memory response to gastrically intubated ovalbumin was 
also assessed. 
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4. LIPOSOMES. 
4.1. Introduction. 
A number of studies has investigated the potential 
of liposomes as delivery systems for the oral 
administration of macromolecules, particularly insulin 
(19-23). Although some of this work met with a modicum 
of success, liposomes are considered as unsuitable for 
the oral delivery of active macromolecules in humans 
since only limited and variable absorption has been 
achieved to date. However, limited uptake of 
macromolecules may lead to the induction of immune 
responses and liposomes may prove effective candidates 
for oral immunisation studies. 
Liposomes which are claimed to be stable in the 
g.i.t. can be easily prepared. 
Oistearoylphosphatidylcholine/cholesterol 1/1 ratio 
(OSPC/CHOL) liposomes are reportedly stable at low pH, 
in the presence of lOmM bile salts and at 37·C in the 
presence of pancreatic lipase (165). However, the 
reported stability of DSPC/CHOL liposomes in the g.i.t. 
has recently been brought into question following work 
involving the incubation of liposomes in simulated 
intestinal media (166). 
A carrier which protects entrapped material from 
degradation in the g.i.t. and encourages uptake via the 
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PP is likely to prove an effective adjuvant in oral 
immunization studies. 
There has been considerable controversy concerning 
the reported absorption of intact liposomes across the 
g.i.t. In 1981, Diwaker et al (167) concluded that they 
were not absorbed intact, but they could still promote 
the intestinal absorption of an entrapped macromolecule 
by protecting it from rapid digestion. More recently 
the intracellular digestion of liposomes by mucosal 
cells has been reported in a vascularly perfused rabbit 
ileum model in vitro, with transport of an entrapped 
marker into the venous effluent as free molecules 
(168). However, a more recent study, concerning both in 
vitro and in situ data, has confirmed that liposomes 
are not taken up by epithelial cells and that liposomal 
entrapment does not facilitate the transport of 
non-absorbable drugs, and prevents the transport of 
absorbable ones (166). 
It had been previously reported, however, that gut 
epithelial cells take up DSPC/CHOL liposomes intact by 
adsorptive endocytosis since the liposomes will be 
fairly 'solid' at 37·C due to the high transition 
temperature of DSPC (169,170). 
If intact liposomes were to reach the serosal side 
of the intestine ,they could then enter either the 
lymphatic system or the portal blood. One study has 
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reported that the majority of the absorbed material 
enters the lymph (21), this would make an immune 
response more likely, since the liposomal material 
would rapidly encounter lymphoid tissue in the draining 
lymph nodes. If the liposomes were to be delivered to 
the general circulation, their fate would then depend 
on factors such as size, surface charge, opsonisation 
and phospholipid composition. Interestingly, DSPC/CHOL 
liposomes are one of the most stable compositions when 
examined in in vitro experiments with plasma (171). 
The potential of liposomes as immunological 
adjuvants was recognised early (171) and there is now 
much literature relating to this. It appears that the 
immunogenicity of most proteins can be enhanced by 
association with liposomes, though no single ideal 
formulation has arisen. It seems that protein does not 
need to be incorporated into the liposome, since 
liposomes have served as adjuvants for a small amount 
of materials adsorbed on the surface, when no 
enhancement was seen for completely encapsulated 
material (173,174). Some success has been achieved with 
liposomes as oral adjuvants. In several studies, 
liposomes have been shown to be effective at inducing 
salivary IgA antibodies against various Streptococcus 
mutans fractions (25-27). Oral administration of BSA in 
liposomes can also lead to an enhanced salivary IgA 
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response (28). In none of these studies were the 
liposomes claimed to be stable in the g.i.t. 
The method chosen for the preparation of liposomes 
in this study is one capable of encapsulating a wide 
variety of materials, with high efficiency, under mild 
conditions into vesicles of variable lipid composition 
(175,176). Mu1ti1amel1ar vesicles were prepared, since 
these afford maximum protection against the effects of 
enzymes, bile salts and extremes of pH in the gut 
(175,176). 
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4.2. Materials and apparatus. 
Distearoylphosphatidylcholine - Sigma Chemical 
Co.,Poole, Dorset, U.K. 
Cholesterol - Sigma 99+% grade. 
Ovalbumin - Sigma Grade III. 
sonic probe - Dawe 7532B, Branson sonic power Co, 
England. 
Rotary evaporator - Buchi, Rotavapor-R, Flawil, 
switzerland. 
Freeze drier - Edwards modulyo, Crawley, Sussex. 
Malvern 26000 laser sizer - Malvern Instruments, 
Malvern. 
4.3. Methods. 
Four batches of liposomes were prepared by the 
method described below. Aliquots were removed for 
determination of particle size, by laser 
diffractometry, and for determination of ovalbumin 
entrapment, by Lowry assay. The liposomal suspensions 
were then adjusted to the required volume for gastric 
intubation according to the protocol described. 
4.3.1. Liposome preparation. 
DSPC 26mg and CHOL 12.8mg were deposited as a thin 
lipidic film on the walls of a 50ml quickfit flask 
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under rotary evaporation from chloroform. The film was 
dried with nitrogen before being resuspended by 
vigorous shaking at 40 e C with 2ml water. The 
preparation was left to stand for 30 minutes to allow 
full rehydration of the lipids and then mixed with 2ml 
(lOOmg/ml) ovalbumin solution and freeze dried. 
Rehydration of the liposomes was achieved by 
addition of 200ul of water at 40°C. The liposomes were 
kept at this temperature for 30 minutes before being 
diluted with 30ml PBS. The liposomes were collected by 
centrifugation at 3000 rpm for 30 minutes and free 
ovalbumin was removed by repeated washing in PBS. 
4.3.2. Ovalbumin entrapment. 
A Iml aliquot of the liposomal suspension was 
sonicated to disrupt the liposomal membranes and the 
protein content was assessed by a Lowry assay (see 
section 2.5.3.). 
4.3.3. Particle size analysis. 
A small aliquot of the liposomal suspension was 
removed and sized on the Malvern 26000 laser sizer 
according to the method published in the technical 
literature. A description of the technique and a 
diagrammatic representation of the apparatus are given 
in section 6.3.3.2. and figure 6.2. 
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4.3.4. Immunisation protocol. 
Male Wistar rats of about 200g were used, divided 
into three groups of eight animals: 
Group A received lmg ovalbumin, 
Group B received blank liposomes, 
Group C received lmg ovalbumin encapsulated in 
liposomes. 
Each dose was given by gastric intubation in 0.4ml 
PBS and each dose for each group of animals was 
repeated over four consecutive days. Sera and saliva 
samples were collected two weeks after the initial 
intubation, diluted in 1% BSA in PBS and stored frozen 
at -20·C until they were assayed by ELISA. All 
subsequent saliva and sera samples were treated in the 
same way after collection. 
4.4. Results. 
4.4.1. Ovalbumin entrapment. 
The mean ovalbumin entrapment in the 1iposomes was 
8.SSmg, which was 4.4% of that added initially. The 
results for each individual batch of liposomes used for 
oral intubation in group C are shown in table 4.1. 
4.4.2. Particle size analysis. 
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The results from the particle size analyses on the 
same four batches of liposomes described above are 
shown in table 4.2. The mean particle sizes of the 
different batches were 5.79, 5.25, 5.77 and 5 . 2 2 ~ m m
respectively. 
4.4.3. Enzyme linked immunosorbent assay. 
The ELISA results are shown in tables 4.3. and 4.4. 
Values are quoted as optical density readings at 405nm, 
for 1/10 dilutions of both sera and saliva. A reference 
wavelength of 690nm was included for the sera 
determination, since this measurement was performed in 
a dual wavelength spectrophotometer which was on short 
term loan to the laboratory. The reference wavelength 
reading was subtracted from the reading at 405nm to 
give the values shown in table 4.3. (sera only). The 
subtraction of this reference value precludes possible 
false positive results in the assay due to anomalies in 
the plastic of the microtitre plate, but this was 
considered an unnecessary precaution and was not 
subsequently used. 
None of the group responses were statistically 
significantly different in an Unpaired Students "t" 
test. 
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Table 4.1. Ovalbumin entrapment in liposomes as 
determined by Lowry assay (mean ±SD n=4). 
Liposome 
batch 
1. 
2. 
3. 
4. 
Mean ±SD 
Ovalbumin 
entrapment(mg) 
9.4 
8.75 
8.75 
8.6 
8.88 ±O.357 
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Ovalbumin 
entrapment(%) 
4.7 
4.4 
4.4 
4.3 
4.4 ±O.173 
Table 4.2. Size analysis of liposomes by laser 
diffractometry (n = 4). 
Batch 1. 2. 3. 4. 
size pm weight % undersize 
118.4 100 100 100 100 
54.9 99.8 100 100 100 
33.7 98.5 99.7 100 100 
23.7 97.3 98.6 99.9 99.8 
17.7 93.5 95.2 98.4 97.9 
13.6 85.9 89.2 91.7 91.5 
10.5 80.6 83.6 83.1 87.0 
8.2 73.9 76.6 73.3 80.9 
6.4 56.6 62.8 56.9 64.5 
5.0 40.7 46.7 40.8 46.8 
3.9 30.6 33.5 29.1 34.3 
3.0 16.2 18.5 16.2 18.2 
2.4 3.6 5.6 4.7 4.6 
1.9 0.7 1.3 1.0 1.3 
1.5 0.2 0.4 0.3 0.7 
1.2 0.1 0.2 0.2 0.4 
mean size pm 5.79 5.25 5.77 5.22 
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Table 4.3. ELISA saliva and sera responses to gastric 
intubation of ovalbumin in liposomes (mean ±SD n=8) 
(i). Saliva. 
IgA IgG 
Group A 0.473 .±0.116 0.427 ±0.028 
Group B 0.453 ±0.092 0.407 ±0.027 
Group C 0.540 ±.0.180 0.434 .±0.028 
( i i) • Sera. 
IgA IgG 
Group A 0.061 ±0.021 0.154 ±0.049 
Group B 0.059 ±0.017 0.160 ±0.035 
Group C 0.066 ±0.017 0.189 ±0.033 
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4.5. Discussion. 
Although the entrapment efficiency of ovalbumin in 
the 1iposomes was low, 4.4% of 200mg added initially, 
it was sufficiently reproducible and efficient to allow 
the intubation of ovalbumin at the required dose of 1mg 
per animal per day, from one batch of liposomes 
prepared per day. The entrapment value was comparable 
with a value published in the literature for the 
entrapment of albumin in the same type of multilame11ar 
vesicles prepared in the same way (albumin at 10mg/m1 
entrapment efficiency of 3.1%) (175). 
The liposomes were heterogeneous in size, but the 
mean size was quite reproducible for the different 
batches. It was thought that much of the material at 
the upper end of the size distribution was lipid 
aggregates and not 1iposomes with entrapped ovalbumin. 
The literature reports that for liposomes prepared by 
this method and sized under an electron microscope, 95% 
of liposomes are <lpm in size after the removal by 
centrifugation of large lipid aggregates (175). The 
removal of large lipid aggregates was not considered 
necessary for our purposes, since the liposomes were to 
be administered orally. Therefore, the actual mean 
particle size of the liposoma1 material was probably 
smaller than that shown in table 4.2. 
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The ELISA results indicated that entrapment of 
ovalbumin in DSPC/CHOL liposomes led to slightly 
greater immune responses following gastric 
administration alone. Both sera and salivary responses 
were slightly greater in the liposomal group, with the 
IgA response more affected in the saliva and IgG more 
so in the sera. However, none of the liposomal group 
responses were statistically significantly greater than 
the equivalent responses from the control group. 
The slightly greater sera responses from the 
liposomal group indicates that there may possibly be 
enhanced transport of liposomally entrapped material 
across the epithelial cells of the gut and passage into 
the blood or lymph. Whether enhanced transport may be 
due to the uptake of intact liposomes, the enhanced 
uptake of entrapped material alone, the protection from 
degradation of entrapped material, or perhaps even a 
combination of one or more of these mechanisms, is not 
known. The slightly enhanced salivary responses from 
the liposomal group may indicate that DSPC/CHOL 
liposome entrapped material gains better access to the 
tissue of the PP than soluble material. However, since 
none of the immune responses for the liposomal group 
were significantly greater than control responses, the 
ELISA results may be better explained by reference to 
the reported lability of DSPC/CHOL liposomes in 
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simulated intestinal media and the reported lack of 
absorption of entrapped markers by intestinal cells 
(166). Therefore, it was decided that the next 
experiment would be performed with polyacrylamide 
~ - ; ;
microparticles ( P A ) , ~ t h e s e e seemed to have greater 
potential as possible oral adjuvants, for reasons 
discussed in chapter 5. 
A major cause of concern was the failure of the 
control group to produce a significant positive 
salivary immune response, relative to the blank group, 
even though the immunisation protocol was identical to 
that in 3.4.3., when a significant positive salivary 
immune response was induced. However, the 'blank' group 
in this experiment had received gastric administration 
of liposomes. It is possible, although unlikely, that 
this produced a non-specific enhancement of the 
salivary immune response such that the background 
"blank' response was raised. These results bring into 
question the statistical significance of the salivary 
immune response achieved in 3.4.3., particularly as 
this was assessed with reference to only two blank 
animals. 
Since a significant positive salivary immune 
response was not reproduced in this experiment, it was 
decided that primed animals would be used in the next 
experiment. We had hoped to use oral administration 
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only at this stage, since this has a number of 
advantages over parenteral, or combined therapy, when 
considering human subjects. It was of interest to see 
how an oral prime might affect the sera response to 
gastrically administered antigen. Therefore, the 
animals in experiments PAl and PA2 (see chapter 5 for 
description) received a priming dose of 20mg ovalbumin 
by gastric intubation. It has been shown that this dose 
administered by gastric intubation is ineffective at 
producing a detectable salivary antibody response in 
mice (148). Therefore, it might prove an effective 
priming dose. However, a different response may be 
induced in rats. The animals were primed two weeks 
prior to the commencement of the repeated gastric 
intubation regime. 
Oral priming with cholera toxin has been shown to 
be superior to parenteral inoculation in generating a 
specific secretory IgA response (95,155), with the 
exception of intraperitoneal priming (155). 
Combinations of crude toxin and toxoid were most 
effective and a single dose of this combination induced 
mucosal priming which was fully developed in two weeks 
(155). The best cellular immune response to cholera 
toxin is obtained when a single i.p. injection is 
followed two weeks later with an intestinal boost (25). 
The effectiveness of an i.p. prime followed by an oral 
boost for producing an effective secretory immune 
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response has been confirmed using ovalbumin in sheep 
(159). 
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5. POLYACRYLAMIDE MICROPARTICLES. 
5.1. Introduction. 
The preparation of polyacrylamide micropartic1es with 
an entrapped macromolecule was first reported in 1975 
(177); with a detailed production procedure being 
published the following year (178). The method was 
subsequently altered to produce more spherical 
particles of a narrower size distribution (179). 
Since this early work, the approach has been 
extensively modified to produce more biodegradable 
particles. For example the polysaccharides dextran and 
starch are first derivatized with acrylic acid glycidyl 
ester and the resulting acrylic polysaccharides are 
then polymerised (180,181). Macromolecules entrapped 
within these polyacryldextran or polyacrylstarch 
microparticles display the same general properties as 
those entrapped in the original polyacrylamide 
microparticles (180,181). 
Polyacrylamide microparticles appear to have 
considerable potential as orally administered 
immunological adjuvants, in particular for the 
stimulation of the secretory immune response. 
Particles of this type have been shown to be effective 
immunological adjuvants for entrapped macromolecules 
when administered to experimental animals by other 
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routes (182-184). Polyacrylamide microparticles are an 
effective adjuvant for entrapped L-asparaginase when 
administered by the intraperitoneal or the intravenous 
route to mice. However, only a weak immune response to 
this enzyme was induced when it was administered 
entrapped in microparticles by the subcutaneous or the 
intramuscular route (184). This indicates that the 
microparticles are not effective adjuvants for an 
entrapped macromolecule for all routes of 
administration. 
The adjuvant properties of this type of acrylic 
microparticle has been confirmed using other entrapped 
macromolecules. In one experiment, human serum albumin, 
entrapped in microparticles and in the soluble antigen 
form, were administered intravenously to mice. The 
microparticles induced a strong antibody response, 
whilst for the soluble form no response was seen (182). 
Simil ar results were obtained when the particulate 
formulation was administered by the intramuscular 
route. The antibody response obtained was similiar to 
that produced with Freund's complete adjuvant (183). 
It was concluded from this work that the 
microparticles functioned as a pure adjuvant, 
amplifying both the cellular and the humoral immune 
responses when administered by certain routes (185). 
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The adjuvant effect is thought to be due to the 
macroporous structure of the microparticles in which 
the entrapped macromolecule is exposed to the 
environment at the surface (181,186,187). The antigenic 
determinants of the entrapped macromolecule are in this 
way exposed to the immunocompetent cells in an 
immobilised form at a high concentration. In addition, 
the micropartic1es have been shown in vitro to be 
readily taken up by macrophages (188,189). The 
macrophages are possibly the most important cells 
involved in presenting antigens to the T helper cells, 
and are responsible for the processing of both soluble 
and particulate antigens. Particulate antigens are 
internalized and processed, after which they are 
presented on the macrophage surface and are then 
recognised by T cells (190). Thus macrophages are 
important in the effective stimulation of a T cell 
dependent immune response. 
Experimental evidence indicates that entrapment of a 
macromolecule within the microparticles does not seem 
to result in major changes of conformation of the 
macromolecule. This was demonstrated when no 
auto-antibody response could be detected to mouse serum 
albumin when it was administered entrapped in 
microparticles to experimental mice (182). Enzymes 
entrapped within these microparticles retain much of 
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their enzymatic activity (178-181,184,187,191). This 
observation provides further evidence that entrapment 
is a "mild" procedure. 
It has been demonstrated that the humoral immune 
response to an entrapped antigen can be assessed using 
standard immunoassay techniques (182-184). 
It has been shown that entrapment of a macromolecule 
in polyacrylamide microparticles confers enhanced 
stability on that macromolecule against both 
proteolytic and heat denaturation (178-181). Entrapment 
of the enzyme, carbonic anhydrase, led to enhanced 
protection against degradation by protease VI, a 
proteolytic enzyme with broad activity (179). 
Furthermore, it has been shown that acidic pH (>1.2) 
does not adversely affect the microparticle matrix 
(187). Therefore, the entrapment of macromolecules 
within these microparticles may lead to enhanced 
protection for the macromolecule against the 
degradative properties of gastric acidity and the 
gastrointestinal enzymes. 
Although the material exposed at the surface of the 
particle is likely to be extensively degraded in the 
normal way, material more centrally located in the 
particle may be better protected. An increase in the 
amount of the macromolecule absorbed may lead to a 
modification of the immune response produced, 
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particularly if the entrapped material is only released 
from the particles slowly. Polyacrylamide 
micropartic1es are only slowly eliminated in vivo, they 
have a half life of 10-15 weeks in the liver and the 
spleen (191). Therefore, it is likely that if the 
particles are taken up by the PP, they will remain at 
this site for some time. It has been suggested that 
most particles taken up by the PP will be sequestrated 
into macrophages and there is little evidence for 
significant transport of particles to other sites in 
the body (71). 
Results have shown that there is considerable 
leakage of ovalbumin from polyacrylamide microparticles 
on storage in vitro (178,179). Since the particle 
matrix is only slowly degraded in vivo, it is likely 
that there wi1 be continued release of entrapped 
material after uptake, if indeed they are taken up. The 
effect of this on the immune response produced is not 
known, but an enhanced or longer sustained response 
might be expected. 
It has been repeatedly demonstrated that 
polyacrylamide microparticles, of the required size 
characteristics, with an entrapped macromolecule can be 
prepared (179,184,188,189,191). 
Microparticles were prepared by the emulsion 
po1ymerisation of acrylamide and bisacrylamide in the 
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presence of the protein to be entrapped. Before the 
microparticles were administered to experimental 
animals, the extent of leakage of the entrapped protein 
was determined. 
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5.2. Materials and apparatus. 
Acrylamide, bisacry1amide and ammonium persu1phate -
Bio-rad electrophoresis purity reagents, Richmond, 
California, U.S.A. 
Ovalbumin - grade III, Sigma chemicals, Poole, England. 
TEMED (N,N,N',N'-tetramethy1ethylenediamine) - Sigma. 
Pluronic F68 - Wyandotte chemical corp., Wyandotte, 
Michigan, U.S.A. 
U1traturrax TP 18-10 - Janke and Kenkel KG, Staufen, 
Breisgau, W.Germany. 
Coulter counter model TA - Coulter Electronics Ltd, 
Harpenden, Hertfordshire, England. 
30pm aperture tube - Coulter Electronics. 
Isoton - Coulter Electronics. 
Polybead polystyrene microspheres (2.88pm) -
Polysciences Inc. Warrington. 
5.3. Methods. 
5.3.1. Micropartic1e preparation. 
100mg ovalbumin, together with 475mg acry1amide and 
25mg bisacrylamide, were dissolved in Srnl O.2M sodium 
phosphate buffer pH 7.4 and (lmM) EDTA and the mixture 
was deoxygenated in a bell jar connected to a vacuum 
pump. 
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The catalyst, 200pl ammonium persulphate O.43M 
(adjusted to pH 7.4 with NaOH) was added and the 
aqueous phase was homogenised together with lOOmg 
Pluronic F68 in 300ml organic solvent consisting of 
chloroform-toluene (1:4). The organic phase had 
previously been deoxygenated by bubbling nitrogen gas 
through for at least 15 minutes, deoxygenation was 
continued during the polymerisation process. 
Homogenisation achieved the production of a 
water-in-oil emulsion and polymerisation was then 
initiated by the addition of 250 ~ l l of the initiator 
N,N,N',N'-tetramethylenediamine. 
After preparation, the particles were allowed to 
sediment over a 15 minute period and the upper organic 
phase was then decanted off. The particles were 
collected by centrifugation at 2500 rpm for 1 hour, 
resuspended and washed repeatedly in buffer before 
finally being resuspended in saline. 
The micropartic1e composition was characterised by 
the T-C nomenclature suggested by Hjerten (192). The T 
indicates the total amount of monomer used (g per 100mi 
solvent) and the C indicates the % of bisacrylamide 
used (w/w) of the total monomers. The particles 
prepared had a T-C of 10-5; this composition gives a 
good entrapment efficiency for proteins whilst not 
causing denaturation. High concentrations of monomer 
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have been shown to cause denaturation of proteins 
(193). 
5.3.2. Ovalbumin entrapment. 
The microparticles were fully resuspended with 
a pasteur pipette and a 25ml syringe and an aliquot was 
removed for amino acid analysis by the method described 
in section 2.6. 
5.3.3. Ovalbumin leakage. 
The microparticles were stored for three months at 
4°C prior to their use. Therefore, it was necessary to 
determine the extent of leakage of the entrapped 
protein. An aliquot of the microparticle supernatant 
was removed from above the sedimented particles and a 
Lowry assay was performed as described in section 
2.5.3. 
5.3.4. Particle size analysis. 
The 30pm aperture tube was fitted to the Coulter 
Counter and the apparatus was calibrated with 
polystyrene microparticles of known size, according to 
the method described in the Coulter Electronics 
technical literature. The apparatus was then cleaned 
thoroughly and the polyacrylamide microparticles to be 
sized were dispersed in Isoton with a mechanical 
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stirrer. A size analysis was then performed, according 
to the method described in the technical literature. 
5.3.5. Immunisation protocols. 
Older and consequently larger animals were used 
in the initial experiments with polyacrylamide 
microparticles (PAl and PA2) since these would be 
easier to handle and a greater volume of saliva could 
be collected. There was also the possibility that the 
secretory immune system might be better developed in 
older animals, so they might produce better immune 
responses. 
The dose of ovalbumin gastrically intubated in 
experiments PAl and PA2 needed to be reduced below that 
which had been given to experimental animals previously 
(in chapters 3 and 4), because of limitations imposed 
by the amount of material entrapped in the 
microparticles. In experiments PAl and PA2, O.5mg 
ovalbumin was gastricaUy intubated, Img had been 
administered in previous experiments. 
In experiments PAl and PA2, animals were killed when 
saliva was collected. This was necessary because a 
licence from the Home Office for recovery experiments 
had not yet been obtained. Consequently a separate 
experiment was run, PA2, to enable the assessment of 
the response to a booster dose of ovalbumin entrapped 
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in microparticles, also administered by gastric 
intubation, two weeks after the repeated gastric 
intubation regimen. 
In experiment PA3, sequential sampling of sera and 
saliva was performed for the first time. ~ h e r e f o r e , , a 
full assessment could be made in the same group of 
animals of any changes in immune responses to the 
gastric intubation of ovalbumin. 
(i). PAl experiment. 
Male Wistar rats of about 300g were used and all 
animals received a priming dose of 20mg of ovalbumin in 
O.Sml of physiological saline by gastric intubation. 
Two weeks later the animals were subdivided into 
three groups of eight animals; 
Group A received O.Smg of ovalbumin entrapped in 
microparticles, 
Group B received blank microparticles without 
entrapped ovalbumin, 
Group E received O.Smg of soluble ovalbumin. 
All doses were administered in O.Sml physiological 
saline by gastric intubation and each of the 
intubations for each group of animals was repeated over 
four consecutive days. Sera and saliva samples were 
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collected two weeks after the commencement of the 
repeated intubation and stored frozen. 
( ii) • PA2 experiment. 
The first part of this experiment was identical to 
experiment PAl. Male Wistar rats of about 300g were 
used and each animal received a priming dose of 20mg 
ovalbumin by gastric intubation. Two weeks later the 
rats were divided into two groups of eight animals; 
Group C received O.5mg of soluble ovalbumin, 
Group 0 received O.5mg of ovalbumin entrapped in 
polyacrylamide microparticles. 
Each dose was administered in 0.5ml physiological 
saline by gastric intubation and each dose for each 
group of animals was repeated over four consecutive 
days. 
Two weeks later all the animals in groups C and D 
received an additional dose of ovalbumin, again by 
gastric intubation; 
Group C received 0.4mg soluble ovalbumin, 
Group 0 received 0.4mg ovalbumin entrapped in 
polyacrylamide microparticles. 
-140-
Each dose was administered in O.Sml physiological 
saline. Sera and saliva samples were collected one week 
after this booster dose and stored frozen. 
In experiments PAl and PA2, sera and saliva samples 
were collected under pentobarbitone, as described in 
chapter 3 and stored frozen until assayed by ELISA and 
RIA. 
(iii). PA3 experiment. 
Male Wistar rats of about 200g were used and all 
animals received a priming dose of Smg ovalbumin in 
physiological saline by intraperitoneal injection. 
Prior to this, sera and saliva samples were collected 
from all the animals. The rats were then subdivided 
into three groups of eight which received the following 
treatment two weeks later; 
Group A received lmg of ovalbumin entrapped in 
microparticles, 
Group B received blank microparticles without 
entrapped ovalbumin, 
Group C received lmg soluble ovalbumin. 
All doses were administered in O.2Sml physiological 
saline by gastric intubation, this volume was easier to 
intubate than O.Sml, and each of the intubations for 
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each group of animals was repeated over four 
consecutive days. Sera and saliva samples were 
collected two weeks after the commencement of the 
gastric intubation and stored frozen. 
Two months after the commencement of the initial 
intubations, all the animals in this experiment 
received a booster dose of lmg ovalbumin by gastric 
intubation in O.25ml physiological saline. Sera and 
saliva samples were then collected four days later and 
stored frozen. 
All sera and saliva samples in experiment PA3 were 
collected from animals anaesthetized by inhalation of 
2% Halothane, as described in chapter 3, and stored 
frozen until assayed by ELISA. 
5.4. Results. 
5.4.1. Ovalbumin entrapment. 
Ovalbumin was included in the initial monomer 
solution at a concentration of 20mg/ml. 7.4% of this 
was entrapped in the microparticles during preparation, 
as determined by automatic amino acid analysis on the 
hydrolysed particles. 
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5.4.2. Ovalbumin leakage. 
20.6% of the entrapped ovalbumin leaked out of the 
particles during storage at 4°C for three months, as 
determined by a Lowry assay on the particle 
supernatant. 
5.4.3. Particle size analysis. 
Four repeat determinations were performed on the 
particles and the mean values obtained were plotted 
(figure 5.1.). The mean (median) particle size was 
2 . 5 5 ~ r n , , with 25% <l.45pm and 75% <4.65pm. 
5.4.4. Enzyme linked immunosorbent assay. 
The positive control samples, both sera and saliva, 
included in the ELISA were obtained from an animal 
which was immunised with 500pg OVA in FCA by i.p. 
injection, the samples were collected 14 days later. 
(i). ELISA results from PAl and PA2 sera and saliva are 
shown in table 5.1. The values quoted are optical 
density readings at 405nm for 1/20 dilutions of sera 
and 1/5 dilutions of saliva. Only results from assays 
performed on the same day are compared directly in the 
table. No standard deviation is included for the 
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Figure 5.1. Mean particle size of polyacrylamide 
microparticles determined by Coulter counter (n=4). 
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10 
positive control sera, because only two determinations 
were performed on this sample. 
Table 5.2. shows the ELISA results from PAl saliva, 
groups Band E, which were re-assayed alongside 
pre-inoculation saliva to determine if the priming dose 
of ovalbumin had proved to be an effective immunising 
dose. Values quoted are optical density readings for 
1/10 dilutions. 
All assay values were low and no significant 
differences were seen between any of the groups for 
sera or saliva responses in experiments PAl and PA2. 
(ii). ELISA results from PA3 sera and saliva samples 
are shown in tables 5.3 and 5.4 respectively. The 
values quoted are optical density readings for 1/20 
dilutions of sera and 1/8 dilutions of saliva. All 
pre-inoculation (p.i.) samples were pooled prior to 
assay. 
A significant positive salivary IgA memory response 
was seen in the group of animals receiving g.i. of OVA 
entrapped in microparticles, group A (significant at 
p <0.01 in Unpaired Student "t" test when compared with 
control group). 
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5.4.5. Radioimmunoassay. 
This alternative immunoassay technique (see chapter 
2 for method) was performed on the samples from PAl and 
PA2 to either confirm the low values generated in the 
ELISA, or to indicate if the ELISA assay was of 
relatively low sensitivity. Since the disappointing 
results obtained had brought into question the 
sensitivity of the ELISA technique. 
The results from RIA of PAl and PA2 sera and saliva 
are shown in tables 5.4. and 5.5. respectively, the 
values quoted are counts per minute for 1/2 dilutions 
of sera and 1/10 dilutions of saliva, both in PBS. 
The positive control included in the RIA was 
obtained from an animal which was immunised with 10mg 
OVA in Freunds incomplete adjuvant by i.p. injection, 
f 11 d b . .. . f 4 1010 . f o owe y Lp. In)ectlon 0 x organlsms a 
B.pertussis 10 days later. The serum sample was 
collected 14 days later. 
This assay confirmed the low values obtained in the 
ELISA and confirmed that there was no significant 
differences between the immune responses of any of the 
groups in PAl and PA2 experiments. 
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Table 5.1. ELISA results for PAl and PA2 sera samples 
(mean ±SD n=8) 
PAl sera 
IgA IgG 
Group A 0.328 ±0.05l 0.707 ±0.210 
Group B 0.334 ±0.056 0.764 ±0.258 
Group E 0.449 ±0.110 0.873 ±0.289 
positive control 1.065 2.830 
PA2 sera 
IgA IgG 
Group C 0.338 ±0.049 0.671 ±.0.213 
Group D 0.263 ±0.O32 0.520 ±0.150 
positive control 0.657 1.830 
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Table S.2. ELISA results for PAl and PA2 saliva samples 
(mean ±SD n=8). 
Group A 
Group B 
Group C 
Group D 
Group E 
positive control 
saliva 
PAl and PA2 
IgA 
0.253 ±0.112 
0.231 ±0.068 
0.232 ±0.080 
0.265.±0.080 
0.292 ±0.138 
0.623 ±0.039 
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saliva 
IgG 
0.216 ±0.026 
0.189 ±0.014 
0.178.=t0.01S 
0.176 ±0.052 
0.190 ±0.096 
0.293 ±0.096 
Table 5.3. ELISA results for PAl saliva assayed with 
pre-inoculation saliva (mean ±SD n=8). 
Pre-inoculation 
Group B 
Group E 
positive control sera n=6 
positive control saliva n=4 
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IgA 
o • 4 37 ±O. 0 6 5 
0.533 ±0.l53 
0.589 ±0.l35 
0.582 ±0.034 
0.504 ±0.030 
Table 5.4. ELISA results for PA3 sera samples (mean ±SD 
n=8) • 
PA3 IgA 
14 day. memory. 
Group A 0.682 ±0.247 0.487 ±0.096 
Group B 0.736 ±,0.172 0.534 ±0.077 
Group C 0.837 ±0.187 0.576 ±.0.023 
Pre-inoculation 0.587 ±0.136 
positive control 0.678 
PA3 IgG 
Group A 1.120 ±0.488 1.155 ±0.489 
Group B 0.794 ±0.216 0.831 ±0.239 
Group C 1.129 ±0.403 1.195 ±0.485 
Pre-inoculation 0.708 ±0.286 
positive control 1.594 
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Table 5.5. ELISA results for PA3 saliva samples (mean 
+SD n=8). 
PA3 IgA 
14 day. memory. 
Group A 0.329 ±0.074 0.593 ±.0.088 
Group B 0.402 ±0.107 0.428 ±0.061 
Group C 0.404 ±0.073 0.434 ±.O. 083 
Pre-inoculation 0.411 ±0.067 
PA3 IgG 
Group A 0.288 .±0.045 0.320 .±0.064 
Group B 0.328 ±0.049 0.370 ±0.058 
Group C 0.259 ±0.030 0.424 ±0.053 
Pre-inoculation 0.332 ±0.07l 
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* 
Table 5.6. Radioimmunoassay results for PAl sera and 
saliva samples, counts per minute (mean ±SD n=8). 
( i). sera 
Group A 
Group B 
Group E 
positive control 
(ii).saliva 
Group A 
Group B 
Group E 
IgA 
1285 ±472 
1310 ±424 
1401 ±.374 
132553 
IgA 
302 +71 
307 +116 
378 ±lSl 
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IgG 
1860 ±601 
1493 ±509 
2344 ±633 
104337 
IgG 
265 ±78 
274 ±89 
340 ±31 
Table 5.7. Radioimmunoassay results for PA2 sera and 
saliva samples, counts per minute (mean +SD n=8). 
( i). sera 
IgA IgG 
Group C 838 ±4l8 1371 ±341 
Group D 520 ±-108 797 ±186 
positive control 115315 91875 
(ii). saliva 
IgA IgG 
Group C 415 ..:1:44 366 ±91 
Group D 442 .:1:157 454 ±91 
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5.5. Discussion. 
The ELISA results from experiments PAl and PA2 were 
disappointing in several respects. Firstly, for the 
immunisation protocols used, the microparticles did not 
appear to be an effective adjuvant, though, this does 
not mean that they might not be so when administered 
according to a different protocol. Secondly, in no 
group was a significant positive salivary antibody 
response achieved. However, a small serum response was 
seen in the control groups, which suggests that small 
amounts of ovalbumin are absorbed intact after oral 
administration. Though the site of absorption is 
unknown. The low levels of circulating antibodies was 
confirmed in an RIA. A small serum response, following 
a single oral administration of a soluble antigen has 
been previously reported in Osborn Mendel rats (28) and 
following repeated gastric or oral administration in 
the Wistar rat (151,152). Most workers reporting serum 
responses in other species have used repeated 
administration, or long term feeding (149-151). 
In considering the salivary response, it is 
important to note that the blank groups were not true 
"blanks", since they had received a 20mg dose of 
ovalbumin by gastric intubation, which was meant as a 
priming dose only. It is conceivable that this initial 
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dose raised ovalbumin specific antibodies in the saliva 
of all animals in experiments PAl and PA2 to such a 
level that the subsequent repeated intubation of 
ovalbumin did not raise the levels further. This could 
explain why PAl animals all showed similiar levels of 
salivary antibody. If this is the case, then the 
immunisation protocol is poorly designed, the initial 
dose is not acting as a priming dose, but as an 
effective irnrnunising dose. This possibility was tested, 
by re-assay of PAl saliva, groups Band E alongside 
pre-inoculation saliva collected from a separate group 
of animals. The results from this assay are shown in 
table 5.2. The ELISA values for the groups in PAl 
re-assayed, were raised above the pre-inoculation 
values, but were not raised significantly. However, the 
saliva from PAl had been repeatedly thawed and 
re-frozen since it had been collected, so there is a 
distinct possibility that there had been some loss of 
IgA binding activity. Therefore, no real conclusions 
can be drawn from these results, but the possibility 
remains that the oral "priming" dose of 20mg ovalbumin 
raised salivary antibodies to such a level, that the 
subsequent repeated intubation of O.5mg per day had no 
effect. The non-reliability of the positive controls, 
both sera and saliva, for IgA has become apparent. 
There is certainly a loss of binding activity of the 
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IgA antibodies in these samples on repeated assay. 
Therefore, in subsequent assays, 35 day sera from 
immunisation protocol (ii) section 2.1.3.1. was used as 
an IgA positive control. 
Effective oral immunisation will result in a 
decrease in the subsequent absorption of orally 
administered antigen, which could also help to explain 
the low salivary responses. In PA2, the booster dose 
was administered only two weeks after the repeated 
dosing; sufficient time had not elapsed to allow the 
production of the cells required to generate a memory 
response in the salivary tissue. The booster dose was 
also low at only O.4mg. In retrospect, it was concluded 
that the protocol for PA2 was not very effectively 
designed. 
Another possibility, though a less likely one, is 
high dose unresponsiveness in the secretory tissue. 
Secretory tolerance to large doses of bacterial 
antigens has been reported in mice (148). 
The most important reagents in the ELISA are the 
second antibodies, the sheep anti-rat immunoglobulins. 
The batch here was not identical to that used 
previously in assays for salivary antibodies. There is 
certainly a possibility of batch to batch variation in 
quality, since the reagent is produced by immunising 
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sheep and is therefore likely to be prone to biological 
variation in response. 
An alternative immunoassay technique was required to 
either confirm the ELISA data, or to indicate low assay 
sensitivity. Therefore, an RIA was performed on the 
samples from PAl and PA2. The RIA showed good 
sensitivity and was capable of detecting very low 
levels of ovalbumin specific antibodies (see chapter 2 
for description of method and assay protocol). This 
work was performed at Beechams Biosciences Research 
Division, Epsom. 
The trends shown with the ELISA for the sera and the 
saliva responses were confirmed with the RIA. With 
control groups response > blank and microparticle group 
responses, and generally blank = microparticle 
responses. Again, none of the group values were 
statistically significantly different. This confirms 
the results shown by the ELISA and demonstrates that 
this technique is sensitive. Therefore, we were 
justified in using ELISA further. 
Since oral priming failed to produce significant 
positive salivary immune responses, the rats in 
experiment PA3 were primed by i.p. injection. Priming 
by the i.p. route is the best way to achieve an 
enhanced secretory IgA immune response to subsequent 
oral challenge with cholera toxin in the rat (155), 
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although i.p. priming may not be effective for 
non-bacterial antigens. We were interested in how an 
i.p. dose might affect the absorption of ovalbumin and 
how this might affect the serum response. 
The older animals used in experiments PAl and PA2 had 
not produced good salivary immune responses, so in PA3 
younger rats were used. In addition, PA3 was run over a 
much longer time course, so the larger rats would have 
become difficult to handle. 
The dose administered to the experimental animals by 
gastric intubation in PA3 was increased. The primary 
and the memory immune responses could now be assessed 
in the same group of animals, since they could now be 
allowed to recover after saliva collection. 
Pre-inoculation samples could now also be taken, to 
allow a full assessment of any changes in immune 
response to OVA. 
A booster dose of soluble ovalbumin was administered 
by gastric intubation, since, although the 
microparticles may not prove to be an effective 
adjuvant for a primary immune response, they may alter 
the memory response in some way. 
Prior i.p. challenge was very effective at priming 
for a positive sera response to orally administered OVA 
and does not block its absorption across the gut. 
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Though parenteral immunisation might be expected to 
decrease the absorption of a subsequently administered 
antigen. Particulate was as effective as soluble 
ovalbumin at producing a primary and a memory sera IgG 
response. Though the sera IgA response to the 
particulate was less than that of the blank group. 
These observations raise the possibility of bolstering 
the serum response to soluble antigens by parenteral 
immunisation followed by oral administration. 
In PA3, particulate antigen produced a significantly 
better salivary IgA memory response than soluble 
antigen although the responses after fourteen days were 
equivalent and did not differ from the blank. Antigen 
persists for months in the lymphoid tissue of immune 
animals and is believed to participate in the induction 
and maintenance of B-cell memory (197). The presence of 
ovalbumin in an immobilised form, since the particles 
are not degraded nor translocated to other sites, or 
the continued leakage of ovalbumin from the particles 
may be responsible for the enhanced memory response. It 
is interesting to note that the best salivary IgA 
response, group A memory response, coincided with the 
smallest sera IgA response. There is transfer of serum 
IgA into the salivary glands, though this differs 
markedly from the transfer into bile in the liver 
(198). Perhaps the low levels of circulating IgA are a 
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consequence of the selective transport of serum IgA 
into mucosal secretions. 
These results raise the possibility of producing 
better secretory immune responses on mucosal 
re-exposure to antigen, if the antigen was introduced 
initially as a particulate. 
In the next experiment, involving butyl 
(2-cyanoacrylate) particles, which are biodegradable, 
the same immunisation protocol as used in PA3 was 
followed. This work allowed us to assess the effect of 
particle size on oral adjuvanticity of a particulate 
dosage form administered orally. 
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6. POLY (2-BUTYLCYANOACRYLATE) PARTICLES. 
6.1. Introduction. 
These particles are easily prepared, their size can be 
altered by physicochemical factors, they adsorb a large 
variety of materials, are biodegradable and biocompatible. 
Formation is achieved by aqueous anionic polymerization of 
butyl 2-cyanoacrylate at low pH in the presence of a steric 
stabilising agent. The influence of stabilisers on particle 
size has been investigated (199). Dextran 70 gave particles 
sized at about 130nm, depending on other physicochemical 
factors (200), but using beta cyclodextrin it was possible 
to prepare particles of about 3000nm. The use of these two 
stabilisers allowed us to assess the effect of particle size 
on the immune responses to ovalbumin following oral 
administration adsorbed to a colloidal carrier. 
There have been several attempts to improve the 
bioavailability of drugs after oral administration by 
association with polyalkylcyanoacrylate particles. Maincent 
et al (201,202) reported enhanced bioavai1ability of 
vincamine after oral administration loaded onto 
nanoparticles. Initially the transfer of particles across 
the intestinal barrier was proposed to explain the modified 
oral absorption, but subsequently the effect was linked to 
an increase in duration of contact with the gut wall. 
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Nefzger et a1 (203) studied the distribution of 
radioactivity following the oral administration of 
radio1abe11ed particles to bile cannulated rats. They 
reported that 10-15% of the administered radioactivity was 
absorbed and found in the bile and urine. However, it was 
suggested that the small amount absorbed probably consisted 
of low molecular weight components in the polymer and it was 
concluded that the main part of the nanoparticle material is 
non-absorbable by rats. Nefzger et al (203) also reported 
the oral adjuvanticity of nanoparticles for adsorbed 
inactivated rabies vaccine. 
The preparation of nanoparticles directly from insulin 
and their oral administration has been reported (39). The 
insulin nanoparticles were biologically active and were 
claimed to be absorbed intact, although direct evidence of 
absorption was not provided. Insulin adsorbed onto poly 
a1kylcyanoacry1ate particle was not active after oral 
administration to rats (38). However, passage across the 
intestine of nanoparticles loaded with insulin after oral 
administration, with the insulin still biologically active 
has been reported (204). 
The uptake of significant amounts of particle loaded 
material across the G i ~ . . seems unlikely, but uptake of 
sufficient material to raise an immune response does seem a 
distinct possibility. 
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The association of antigens with poly (methyl 
methacrylate) nanoparticles leads to a good adjuvant effect 
(205,206) and the particle size of the polymer proved to be 
an important parameter for adjuvant activity (207,208). 
The adsorption of ovalbumin onto butyl 2-cyanoacrylate 
particles stabilised with dextran 70 and with beta 
cyclodextrin was assessed, but this involved irreversible 
aggregation of the particles. Therefore, batches of the 
particles were prepared by an identical method, mixed with 
ovalbumin and orally administered to experimental animals. 
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6.2. Materials and apparatus. 
Butyl 2-cyanoacrylate - Henkel, Sichel-werke, Hanover, 
W.Germany. 
Dextran 70 - Sigma.(subsequently termed dextran). 
Beta cyclodextrin - Sigma.(subsequently termed 
cyclodextrin). 
Ovalbumin, Grade III - Sigma. 
Malvern 2600 laser diffractometer - Malvern 
Instruments, U.K. 
Uvikon 860 spectrophotometer - Kontron. 
Sonic bath - Decon FS 100. 
MSE High Speed 25. 
MSE Centaur 2 
Photon correlation spectroscopy. 
Autocorrelator - Malvern K7025. 
Helium/neon laser - Siemens LGK 7626. 
Commodore Pet 200l-32N microprocessor - Commodore, 
U.S.A. 
6.3. Methods. 
6.3.1. Particle preparation. 
O.25ml of butyl 2-cyanoacrylate was added dropwise 
to 24.75ml of a filtered (0.2pm membrane, Whatman) 
aqueous solution of the stabilising agent in 
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approximately O.OIM HCI at pH 2.25 at 20·C. Dextran 
0.5% w/v and cyclodextrin 1% w/v were used separately 
as stabilizing agents to prepare different sized 
particles. 
The preparation was stirred with a glass covered 
magnetic stirrer and the rate was adjusted to fully 
disperse the monomer. Polymerisation was then allowed 
to go to completion over 2 hours. The dextran 
stabilised particles were filtered through a sintered 
glass funnel (grade 4, pore size 11-16pm). 
0.2% w/v poloxamer 188 was added to the particle 
suspensions to de-aggregate the cyclodextrin stabilised 
particles. Poloxarner 188 was also added to the dextran 
stabilised particles to ensure that the two particulate 
formulations differed only in particle size, due to the 
different stabilisers used in their preparation. 
6.3.2. Ovalbumin adsorption. 
The particles were fully resuspended by sonication 
in a sonic bath, a 10ml aliquot was removed and the pH 
was adjusted to 7.4 with the addition of O.lM NaOH. 
Ovalbumin was added and the suspension was stirred for 
30 minutes. The suspension was then either intubated 
into experimental animals, or the particles were 
isolated by centrifugation and the protein adsorption 
was assessed by a Lowry assay (see 2.5.3.) on the 
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supernatant. The protein content of the supernatant was 
subtracted from the amount of protein added initially 
to indicate the amount adsorbed to the particles. 
Cyclodextrin stabilised particles were collected by 
centrifugation at 4,000rpm for 20 minutes and dextran 
particles were collected by centrifugation at 2l,000rpm 
for two hours. 
6.3.3. Particle size analysis. 
6.3.3.1. Photon correlation spectroscopy (PCS). 
Dextran stabilised particles were sized by pes. The 
instrument used was based on a commercially available 
Malvern system (fig 6.1.). The sample, held in a 
thermostatted water bath at 25 ± O.OS·C, was 
illuminated by the laser and the resulting scattered 
light was detected at 90 0 by a variable angle photon 
detection system which transmitted the signal to a 
Malvern K702S, 64-channel, multibit correlator. This 
was interfaced with a microprocessor to give a print 
out of the correlation data. Full details of this 
sizing technique and its validation for the sizing of 
p(BCA) particles has been described previously from 
this laboratory (209). 
Samples were diluted before measurement with 
distilled water freshly filtered through a 0.2pm 
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Figure 6.1. Diagramatic representation of photon 
correlation spectroscopy apparatus. 
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membrane filter. The calculated particle diameter and 
the polydispersity index vary according to the sample 
time chosen for the size determination, so this was 
varied to produce optimal conditions. The sample was 
then analysed 10 times to give an average for the 
particle diameter and the polydispersity index. 
6.3.3.2. Laser diffractometer. 
The low power visible laser transmitter produces a 
parallel monochromatic beam of light which illuminates 
the particles which are dispersed in the constantly 
stirred sample cell. The incident light is diffracted 
by the particles to give a diffraction pattern. The 
angle of diffraction is dependent on the angle of 
curvature at the particle surface and therefore 
dependent on particle size. The diffracted laser light 
is focused by a Fourier transform lens onto a 31 ring 
solid state photoelectric detector system. Each ring 
relates to a particle size and the intensity of light 
hitting the ring indicates the number of particles of 
this size. The Fourier transform lens always focuses 
light from similiar sized particles onto the same ring 
detector irrespective of the particles position in 
space. As particles enter and leave the illuminated 
field the diffraction pattern evolves, always 
reflecting the instantaneous size distribution in this 
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area. The ring detector system is interfaced directly 
to a desktop computer which reads the diffraction 
pattern and performs the necessary inteqration. The 
computer uses the method of non-linear least squares 
analysis to find the size distribution which most 
closely fits the diffraction pattern obtained (See fig 
6.2. for diagramatic representation of this equipment). 
6.3.3.3. Coulter counter. 
The cyclodextrin stabilised particles were also 
sized using a Coulter Counter to confirm the data from 
the laser diffractometer. The Coulter Counter was 
calibrated and counting performed as described in 
chapter 4. 
6.3.4. Experimental protocol. 
Male wi star rats of about 200g were used and all the 
animals received a priming dose of Smg OVA in 
physiological saline by intraperitoneal injection. 
Prior to this, sera and saliva samples were collected 
from all the animals and stored frozen. The rats were 
then divided into four groups of eight animals which 
received the following treatment two weeks later: 
Group A received lmg of ovalbumin in O.25ml of 
cyclodextrin stabilised particles. 
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Group B received O.25ml of a combined suspension of 
cyclodextrin and dextran stabilised particles. 
Group C received lmg of ovalbumin in O.25ml of 
physiological saline. 
Group 0 received lmg of ovalbumin in O.25ml of dextran 
stabilised particles. 
It was considered unnecessary to run 'blank' groups 
for both dextran stabilised and cyclodextrin stabilised 
particles individually since this would be wasteful of 
experimental animals and would not provide any more 
information than could be obtained from having one 
combined 'blank' group. Therefore, group B was a 
combined 'blank' group and received g.i. of an equal 
mixture of both sized particles. All doses were 
adjusted to pH 7.4 with O.lM NaOH and were administered 
by gastric intubation. Each of the intubations for each 
group of animals was repeated over four consecutive 
days and sera and saliva samples were collected two 
weeks after the commencement of the gastric intubations 
and stored frozen. 
Two months after the commencement of the initial 
intubations, all the animals received a booster dose of 
lmg OVA by gastric intubation in physiological saline. 
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Sera and saliva samples were then collected four days 
later and stored frozen until assayed by ELISA. 
6.4. Results. 
6.4.1. Ovalbumin adsorption. 
Ovalbumin was efficiently adsorbed to the surface of 
both cyclodextrin and dextran stabilised p(BCA) 
particles and adsorption increased as the concentration 
of the protein was increased (table 6.1.). At a fixed 
concentration of 4mg/ml, adsorption to the particle 
surface was reproducible (table 6.2.). The adsorption 
to cyclodextrin stabilised particles was slightly 
greater than to dextran stabilised particles (table 
6 .2. ) • 
6.4.2. Particle size determination. 
6.4.2.1. Particle size analysis of dextran stabilised 
poly 2-butylcyanoacrylate particles by photon 
correlation spectroscopy. 
Ten repeat determinations were performed on the 
sample, the mean pes diameter was 215.3nm ±12.0 (mean 
±SO n=lO), with polydispersity of 0.185 ±0.039. This 
was converted to an actual particle diameter by a 
computer program written by Douglas (209), the length 
number mean diameter was 100.3nm (table 6.3.). 
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6.4.2.2. Particle size analysis of beta cyclodextrin 
stabilised poly 2-butylcyanoacrylate particles by laser 
diffractometry. 
Three repeat determinations were performed and the 
size distributions obtained are shown in table 6.4. The 
mean sizes obtained were 3.26pm, 3.26pm and 3.25pm. 
6.4.2.3. Particle size analysis of beta cyclodextrin 
stabilised poly 2-butylcyanoacrylate particles by 
Coulter counting. 
Four repeat determinations were performed on the 
particles and the means of these determinations were 
plotted (figure 6.3.). The mean particle size was 3.2pm 
with 25% <2.1pm and 75% <4.25pm. 
6.4.3. Enzyme linked immunosorbent assay. 
The IgG positive control sample was the same as that 
used previously in chapter 5, section 5.4.4. for 
description. The IgA positive control sample was 
obtained from an animal that was immunised as described 
in section 2.1.3.1. (ii), the sample was collected 
after 35 days. 
(i). ELISA results for sera samples are shown in table 
6.5. Values shown are optical density readings at 405nm 
for 1/10 dilutions of sera. A significant positive sera 
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IgG response was seen after 14 days for group 0 
animals. 
(ii). ELISA results for saliva samples are shown in 
table 6.6. Values shown are optical density readings at 
405nm for 1/5 dilutions of saliva. Significant positive 
salivary IgA responses were seen for both groups A and 
Dafter 14 days, and for group 0 memory response. 
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Table 6.1. Adsorption of ovalbumin to beta cyc10dextrin 
and dextran 70 stabilised poly 2-butylcyanoacrylate 
particles. 
beta cyc10dextrin 
Ovalbumin stabilised particles 
added (mg) Ovalbumin bound 
(mg) % of added 
10 5.36 53.6 
17.5 10.70 61.4 
25 16.90 67.6 
32.5 22.94 70.6 
40 33.52 83.8 
47.5 40.90 86.1 
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Dextran 70 
stabilised particles 
Ovalbumin bound 
(mg) % of added 
6.46 64.6 
10.96 62.6 
17.44 69.8 
23.68 72.9 
30.10 75.3 
36.94 77.8 
Table 6.2. Adsorption of ovalbumin at concentration of 
4mg/ml to beta cyclodextrin and dextran 70 stabilised 
poly 2-butylcyanoacrylate particles (mean ±SD n=4). 
Ovalbumin 
added mg. 
40 
40 
40 
40 
Mean 
+SD 
beta cyclodextrin Dextran 70 
stabilised particles. stabilised particles 
Ovalbumin bound Ovalbumin bound 
mg. , added. mg. % added. 
32.92 82.3 29.32 73.3 
32.26 80.7 28.96 72.4 
32.56 81.4 29.14 72.9 
31.42 78.6 29.02 72.6 
32.29 80.7 29.11 72.8 
+0.640 ±0.159 
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Table 6.3. Particle size analysis of dextran 70 
stabilised poly 2-butylcyanoacrylate particles by 
photon correlaton spectroscopy (mean n=lO). 
LN (diameter) Diameter (nm) cumulative , 
undersize 
3.0 20.1 .02 
3.15 23.3 .08 
3.3 27.1 .26 
3.45 31.5 .75 
3.6 36.6 1.94 
3.75 42.5 4.45 
3.9 49.4 9.09 
4.05 57.4 16.62 
4.2 66.7 27.31 
4.35 77.5 40.61 
4.5 90.0 55.11 
4.65 104.6 68.95 
4.8 121.5 80.52 
4.95 141.2 89.0 
5.1 164.0 94.44 
5.25 190.6 97.5 
5.4 221.4 99.01 
5.55 257.2 99.66 
5.7 298.9 99.91 
5.85 347.2 99.99 
Geometric mean diameter = 92.1 nm 
Length number mean diameter = 100.3 nm 
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Table 6.4. Particle size analysis of beta cyclodextrin 
stabilised poly 2-butylcyanoacrylate particles by laser 
diffractometry (mean n=3). 
cumulative weight % undersize. 
Run number 
Size 
(pm) 1. 2. 3. 
118.4 100.0 100.0 100.0 
54.9 100.0 100.0 100.0 
33.7 100.0 100.0 100.0 
23.7 100.0 100.0 100.0 
17.7 100.0 100.0 100.0 
13.6 100.0 100.0 100.0 
10.5 100.0 100.0 100.0 
8.2 100.0 100.0 100.0 
6.4 98.6 98.6 98.6 
5.0 88.3 88.3 88.4 
3.9 69.3 69.3 69.6 
3.0 43.3 43.3 43.3 
2.4 21.7 21.7 21.7 
1.9 11.7 11.7 11.6 
1.5 8.2 8.2 8.1 
1.2 6.9 6.9 6.9 
Mean size 3.26 3.26 3.25 
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Table 6.5. ELISA results for BCA sera samples (mean +SD 
n=8) • 
BCA sera IgG. 
14 day response. Memory response • 
Group A 0.730 .±0.385 0.665 ±0.430 
Group B 0.485 +0.063 0.514 ±0.320 
Group C 0.416 +0.114 0.359 ±0.161 
Group 0 0.681 ±0.050 * 0.426 ± 0.151 
Pre-inoculation 0.318 ±0.078 
positive control 2.249 ±0.093 
BCA sera IgA. 
14 day response. Memory response. 
Group A 0.542 ±0.278 0.345 ±0.098 
Group B 0.369 ±.0.191 0.303 ±O. 0 57 
Group C 0.285 ±0.038 0.267 ±0.055 
Group D 0.336 ±0.017 0.306 ±0.061 
Pre-inoculation 0.286 ±0.025 
positive control 1.108 +0.052 
-180-
Table 6.6. ELISA results for BCA saliva samples (mean 
iSD n=8). 
BCA saliva IgG. 
14 day response. Memory response. 
Group A 0.292 ±0.02l 0.330 ±0.044 
Group B 0.219 ±0.042 0.247 ±O. 0 36 
Group C 0.226 ±0.023 0.381 +0.168 
Group D 0.286 ±0.044 0.396 ±0.072 
Pre-inoculation 0.291 ±0.045 
positive control 0.937 ±0.121 
BCA saliva IgA. 
Group A 
Group B 
Group C 
Group D 
14 day response. 
0.717 ±.0.176 * 
0.424 ±.D.083 
0.489.±D.117 
0.654 ±0.104 * 
Pre-inoculation 0.507 ±0.070 
Positive control 1.016 ±0.277 
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Memory response. 
0.557 ±0.152 
0.512 ±0.101 
0.578 ±0.103 
0.708 ±0.116 * 
6.6. Discussion 
The adsorption of OVA to cyclodextrin stabilised 
particles was slightly greater than to dextran 
stabilised particles at a concentration of 4mg/ml OVA. 
This indicates that the stabilising agent, which is 
exposed at the particle surface (209), has an effect on 
adsorption. Since otherwise, the smaller dextran 
stabilised particles, with a much greater surface area 
available, would be expected to adsorb more material. 
The efficient adsorption of ovalbumin to p(BCA) 
particles is a consequence of the high affinity of 
proteinaceous material for the very hydrophobic 
particle surface. 
It is possible that material adsorbed after oral 
administration might affect M-cell uptake of the 
particles in a negative or a positive way, but this is 
impossible to predict. Immediately after injection into 
the bloodstream, colloidal particles become coated with 
various components of the blood (opsonisation). The 
nature of the surface coating of particles can have a 
profound effect on their uptake by macrophages and 
their distribution in vivo. Distribution effects 
related to particle hydrophobicity/hydrophilicity and 
the interaction with biological macromolecules may have 
direct counterparts in the gastrointestinal tract (73). 
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After oral administration of p{BCA) particles OVA may 
be partially displaced on the particle surface due to 
competition with other materials. The interaction of 
proteins at interfaces is a common phenomenon and when 
a non-biological surface contacts whole blood, 
immediate adsorption of dissolved plasma proteins and 
other substances occurs onto the surface (210). Though, 
the overall dose administered to the animals is 
unaffected, the possible interactive behaviour of the 
particles with dietary constituents, endogenous 
bacteria and physiological components of the git,mucins 
etc., cannot be predicted. So, it is not known how much 
of the ovalbumin remains adsorbed to the particles in 
vivo • 
............. 
The sera IgG response to dextran stabilised 
particles was significantly greater than the control 
group response after 14 days (significant at p< 0.001 
in Unpaired Student "t" test) (table 6.5.). The mean 
IgG ELISA value for dextrin stabilised was greater than 
that for dextran stabilised particles, but since 
the standard deviations were so large, this response 
was not significantly enhanced compared to the control 
group. This result raises the possibility of inducing 
enhanced sera immune responses to orally intubated 
antigens, if the antigen is adsorbed to a particulate 
carrier. It seems that a more reliable response is 
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induced if the carrier is sized about lOOnmas opposed 
to about 3 ~ m , , though this conclusion is based on a 
very limited amount of data. 
The salivary IgA responses for both dextran and 
cyclodextrin stabilised particles were significantly 
greater than the control group response after 14 days 
(significant at p <0.02 and p <0.01 respectively in 
Unpaired Student "t" tests when compared with the 
control group response) (table 6.6). The salivary IgA 
memory response to dextran stabilised particles 
was significantly greater than the control group memory 
response (significant at p<0.05 in Unpaired Student "t" 
test). 
Therefore, as expected, salivary immune responses to 
OVA were enhanced when OVA was gastrically intubated 
adsorbed to a particulate carrier. This result is in 
agreement with the results obtained in chapter 5, 
although there are important differences in the 
enhanced salivary response obtained. With p(BCA) 
particles, significantly enhanced salivary responses 
were detected after 14 days. This was not so with 
polyacrylamide microparticles in chapter 5, where only 
the salivary memory response was enhanced. We feel that 
this difference in responses to the two particulate 
carriers is a consequence of the degradation of p(BCA) 
after uptake into the PP. The high percentage 
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degradation of p(BCA) and the accompanied release of 
adsorbed drug over a period of several days has been 
reported in vitro (211). After uptake, the particle 
matrix will begin to degrade and adsorbed OVA will be 
released into the local environment to induce an immune 
response. As explained in chapter 5, polyacrylamide 
particles degrade very slowly and OVA is entrapped 
within the matrix of the particles. Therefore, the 
particles are likely to remain intact at the site of 
uptake, and OVA is likely to be released from the 
microparticles only very slowly. Perhaps then, it is 
easy to understand why, with polyacrylamide 
microparticles, the short term salivary immune response 
is not enhanced, though the memory response is. 
Whether the enhanced immune responses seen with 
p(BCA) particles is a consequence of better uptake of 
the particles by macrophages etc., slow release of 
adsorbed OVA into the local environment, or due to 
enhanced uptake of OVA by the PP since it is adsorbed 
to particles is unknown. Though it seems likely that a 
combination of these effects will contribute to the 
enhanced immune responses seen. The salivary IgA memory 
response was enhanced for the group which was intubated 
with dextran stabilised particles. This probably 
indicates that at least some of the particle matrix 
with adsorbed OVA is still intact after a two month 
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period. Perhaps this result indicates that dextran 
stabilised particles are less readily degraded than 
cyclodextrin stabilised, though there is no evidence in the 
literature to support this. 
The results obtained indicate that p(BCA) particles 
may be taken up with adsorbed OVA, probably by M-cells, 
after gastric intubation. Though we have no direct 
evidence of uptake. The enhanced immune responses may 
be a consequence of enhanced uptake of OVA associated 
with particles, without uptake of the particles 
themselves, or the results may be due to protection of 
OVA against degradation by the particles, again leading 
to enhanced uptake of OVA, but not the particles. 
Therefore, an electron microscopy study was undertaken 
with gold labelled p(BCA) particles in an attempt to 
show directly the uptake of p(BCA) particles by 
M-cells. 
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7. ELECTRON MICROSCOPY. 
7.1. Introduction. 
To aid in the design of effective peroral vaccines, 
there is a need for a more fundamental understanding of 
the various factors governing the uptake of particles 
by M-cells. One rather limited study on the uptake of 
several different particulates by PP, indicated that 
particle surface properties as well as size determines 
uptake (73). It is therefore of great interest to 
identify and define the different physicochemical 
properties of particles which may facilitate their 
uptake by M-cells. To investigate the physicochemical 
features that determine uptake in vivo, it is necessary 
first to be able to identify M-cells and secondly to 
quantify the uptake process. This chapter reports 
initial work to identify M-cells in the follicle 
associated epithelium overlying a PP in the rat small 
intestine. To aid this identification, p(BCA) particles 
were labelled with colloidal gold and introduced into a 
gut loop prepared around a grossly visible PP in the 
rat ileum. The uptake of p(BCA) particles by the 
M-cells would provide evidence that these particles are 
suitable candidates for oral immunisation studies. 
In order to study the tissue in question under the 
electron microscope, a detailed process of fixation and 
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processing is required to prepare the tissue. The 
neccesary general steps required in the process of 
electron histology are as follows: 
A. Fixation: killing the tissue, but at the same time 
preserving faithfully all the tissue fine structure as 
near as possible to its form in life. 
B. Block staining: rendering the preserved fine 
structure visible in the electron microscope by causing 
certain components to attract heavy metal ions and thus 
to scatter electrons differentially. 
c. Dehydration: remove water from tissue and replace it 
with inert fluid miscible with water and infiltrating 
fluid. 
D. Infiltration: infiltrating fluid introduced which 
can be easily hardened into an elastic solid. 
E. Polymerisation: hardening of infiltration fluid to 
produce a solid matrix to support tissue. 
F. Sectionning: slicing the block into ultra-thin 
sections < 6 0 0 ~ ~ thick. 
G. Mounting: transferring different sections to copper 
support grids for insertion into the electron 
microscope. 
H. Section staining: increasing the existing 
differential electron scattering power (contrast) of 
the tissue constituents by reacting the mounted 
sections with heavy metal solutions. 
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The tissue sections are now ready for examination in 
the electron microscope. 
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7.2. Materials and apparatus. 
Pentobarbitone sodium 60mg/ml - 'Sagatal' M+B 
veterinary, Oagenham, Kent. 
Primary fixative - 2% glutaraldehyde in O.lM phosphate 
buffer pH 7.2. 
Glutaraldehyde EM 25% - TAAB Laboratories Ltd, Reading, 
Berks. 
Osmium tetroxide in Millonigs buffer 
solution A. 2.26g NaH 2 P04 • 2H 20 in lOOml water. 
solution B. 2.52% NaOH. 
solution C. 5.4% glucose in water. 
Approximately l5ml of solution B was added to 75ml 
of solution A until pH 7.2-7.4 was reached and 19 of 
Osmium tetroxide was dissolved in this, 10ml of 
solution C was then added to produce the fixative. 
Osmium tetroxide - JMC, Royston, Herts. 
Propylene oxide - Fisons, Loughborough. 
Embedding medium 
Equal parts of Araldite monomer and hardener ODSA 
with 1 drop of accelerator BOMA for each ml of 
embedding medium used. The plastics were thoroughly 
mixed before use. 
Epoxy resin Araldite CY212 - TAAB. 
DDSA dodecyl succinic anhydride hardener 964, EM grade 
- TAAB. 
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BOMA benzyldimethylamine - TAAB. 
Toluidine blue stain - 1% toluidine blue in 0.05M 
phosphate buffer pH 7.2. 
Lead citrate (Reynolds) stain kit - EM scope Labs. 
Ltd, Ashford, Kent. 
Automatic micro-osmometer - Roebling, Berlin, W.G. 
LKB 7800 Knifemaker. 
Huxley ultramicrotome - Cambridge. 
Electron microscope EM 410 Phillips 
7.3. Methods. 
7.3.1. Preparation of colloidal gold containing poly 
butyl cyanoacrylate particles.(This work was performed 
on my behalf by my colleague J.Wright.) 
Colloidal gold was prepared according to the method 
of Frens (212), 1m1 chloroauric acid in 50ml double 
distilled water was heated to boiling 2ml trisodium 
citrate (1%) was added and the solution boiled for 5 
minutes. The solution rapidly turned blue and then red 
to indicate that particle formation was complete, a 
size analysis was then performed by pes. 
Four ml of colloidal gold was incubated for 15 
minutes with 40mg Pluronic Fl27, to stabilise the 
colloid, and was then added to 20.75ml of dextran 70 1% 
w/v in O.OlM Hel pH 2.25. Poly 2-buty1 cyanoacrylate 
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particles were prepared according to the method of 
Douglas et al (200), outlined in section 6.3.1. 
7.3.2. Gut loop preparation. 
One male Wi star rat of about 200g was used, which 
was fasted overnight. The animal was anaesthetized by 
i.p. injection of Sagatal 60mg/Kg body weight and the 
abdominal cavity was entered. A PP was identified on 
the serosal side of the intestine and a Scm gut loop 
was prepared around this structure.O.Sml of the 
particle suspension was injected into this gut loop and 
the intestines were replaced in the abdominal cavity 
which was resealed with a clamp. 
About 30 minutes later, the gut loop was removed 
from the abdominal cavity and immersed in the primary 
fixative. Under a dissecting microscope, the PP was 
removed from the surrounding mucosal tissue with the 
aid of a needle and placed in fresh primary fixative 
for 3 hours. 
7.3.3. Tissue processing. 
The tissue was placed in the primary fixative for 3 
hours at room temperature, which was then pipetted off 
and replaced with O.1M phosphate buffer pH 7.2 
containing 4% sucrose. The buffer solution was then 
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replaced with further buffer and the tissue was allowed 
to soak at room temperature overnight. The tissue was 
then further washed by replacement of the buffer, which 
was in turn replaced by Osmium tetroxide solution for 
tissue staining. The tissue remained in Osmium 
tetroxide solution for 1 hour, then rinsed in 50% 
ethanol. Dehydration of the tissue was achieved with 
successive replacement of the 50% ethanol with 70%, 90% 
and then 100% ethanol. At each stage, the tissue was 
allowed to equilibrate in the ethanol for about 15 
minutes. The tissue was then placed in propylene oxide 
for two 15 minute periods before being left overnight 
in a SO/50 solution of propylene oxide and embedding 
medium at room temperature. This solution was replaced 
with full strength embedding medium and left for 24 
hours at room temperature, before being placed in 
rounded moulds and polymerised for 7 days at 60°C. 
Thick plastic sections stained with toluidine blue 
were prepared and viewed under the light microscope to 
establish the orientation of the tissue. Ultrathin 
sections were then cut from the block, mounted on 
copper grids and stained with lead citrate prior to 
examination in the EM 400. 
General reference (213). 
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7.4. Results. 
7.4.1. Particle size analysis. 
(i). Colloidal gold. 
Nine repeat determinations were performed on the 
colloidal gold sample to be incorporated into the 
p(BCA) particles. The mean PCS diameter was 35.87 
±6.21nm (mean ±SO n=9), with polydispersity of 0.376 
±O.087. This was converted to an actual particle 
diameter as described in section 6.4.2.1., the length 
number mean diameter was 8.8nm (table 7.1.). 
(ii). Poly 2-butylcyanoacrylate particles. 
Nine repeat determinations were performed on the 
particles, the mean pes diameter was 208.4 ±6.28nm 
(mean ±SO n=9), with polydispersity of 0.101 ±O.048. 
This was converted to an actual particle diameter as 
described in section 6.4.2.1., the length number mean 
diameter was 135.lnm (table 7.2.). 
7.4.2. Electron micrographs of putative M-cel1s. 
Electron micrographs of two putative M-ce11s are 
shown in figures 7.1. and 7.2. at magnification of 
x6,485 and x11,923 respectively. 
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Table 7.1. Particle size analysis of colloidal gold by 
photon correlation spectroscopy (mean n=9). 
LN (diameter) Diameter (nm) cumulative % 
undersize 
1.5 4.5 8.16 
1.65 5.2 18.25 
1.8 6.0 29.85 
1.95 7.0 42.27 
2.1 8.2 54.64 
2.25 9.5 66.10 
2.4 11.0 75.99 
2.55 12.8 83.93 
2.7 14.9 93.98 
2.85 17.3 96.64 
3.0 20.1 98.24 
3.15 23.3 99.14 
3.3 27.1 99.84 
3.45 31.5 99.94 
3.6 36.6 99.98 
3.75 42.5 100.00 
Geometric mean diameter = 7.5 nm 
Length number mean diameter = 8.8 nm 
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Table 7.2. Particle size analysis of butyl 
2-cyanoacrylate particles, with incorporated colloidal 
gold, by photon correlation spectroscopy (mean n=9). 
LN (diameter) Diameter (nm) 
3.6 36.6 
3.75 42.5 
3.9 49.4 
4.05 57.4 
4.2 66.7 
4.35 77.5 
4.5 90.0 
4.65 104.6 
4.8 121.5 
4.95 141.5 
5.1 164.0 
5.25 190.6 
Geometric mean diameter = 128.8 nm 
Length number mean diameter = 135.1 nm 
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cumulative , 
undersize 
0.01 
0.05 
0.24 
1.00 
3.37 
9.26 
20.83 
38.82 
60.97 
82.55 
99.19 
100.00 
Figure 7.1. Electron micrograph of putative M-cell in 
the epithelium overlying the Peyer's patch in a Wistar 
rat. x 6,485. 
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Figure 7.2. Electron micrograph of putative M-cell in 
the epithelium overlying the Peyer's patch in a Wistar 
rat. x 11,923. 
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7.5. Discussion. 
The cells could not be identified under light 
microscopy and a careful study of the pp tissue in the 
electron microscope was required. But this was mainly 
due to the very limited amount of epithelial tissue 
available to study in the section. The orientation of 
the PP in the block could only be controlled with great 
difficulty since the specimen was so small, about 2mm. 
So it is left to chance to govern what angle the PP was 
sectioned. Consequently, the specimen may not 
necessarily have been sectioned at an angle appropriate 
to the inclusion of much epithelial tissue in the 
section. It was very easy to lose some tissue from the 
specimen during removal, processing etc. and any lost 
tissue was likely to be the epithelial tissue since 
this tissue is surface located and is easily shed. 
Therefore, it is easy to see why there was so little 
epithelial tissue present in the section. 
Since the orientation of the tissue in the block 
could not be controlled, this led to sectioning at an 
oblique angle which further complicated the 
identification of M-cells. However, when a section of 
epithelium that had not been cut at a particularly 
oblique angle was identified under the microscope, the 
subsequent identification of the putative M-cells was 
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not very difficult. The epithelium was examined 
systematically until a cell appeared whose microvilli 
were noticeably different from those of the adjacent 
ordinary epithelial cells. The cells were then 
photographed for closer study. 
Putative M-cells were identified in the epithelium 
overlying the PP, figs 7.1 and 7.2. These cells 
displayed a number of characteristic features which 
have been ascribed to M-cells by several workers, they 
did not display regular 'finger-like' microvilli on 
their apical surface, like ordinary absorptive cells, 
but displayed shorter irregular microvilli (85-87). The 
cells had a thin bridge of apical cytoplasm, with 
abundant vesicles, fig 7.2, and the cytoplasm 
surrounded several intrusive cells which appeared to be 
lymphocytes (87). These intrusive cells are not within 
the M-cell cytoplasm, but in the intercellular space 
that indents the M-cell cytoplasm, forming a "central 
hollow· (80). The cells displayed less electron dense 
cytoplasm and more electron dense mitochondria than the 
adjacent ordinary epithelial cells (214). Therefore, 
although it cannot be stated categorically that these 
cells identified in the epithelium overlying the PP are 
M-cells, all the available evidence would suggest that 
they are. 
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No particles were observed associated with the 
epithelial surface and none were observed in M-cells. 
This may indicate that insufficient colloidal gold was 
incorporated into the particles to render them visible 
in the microscope, or it may indicate that there is a 
fundamental flaw in the experimental technique. It 
seems more likely that the gold incorporation technique 
was unsuccessful. 
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8. Final discussion and conclusions. 
The overall aim of this project was to enhance 
immune responses to the chosen model protein following 
oral administration. To achieve this the model protein 
was associated with colloidal carriers. We were 
particularly interested in the salivary IgA response, 
however, a number of problems were encountered in the 
determination of salivary IgA by ELISA. Rat IgA could 
not be obtained commercially and as a result it was 
impossible to perform a quantitative assessment of the 
ELISA technique. Also, unfortunately, the quality of 
the sheep anti rat IgA conjugate, the most important 
reagent in the ELISA, could not be determined. The only 
option open to us, was to initially prove the assay 
system capable of detecting IgA in the serum, and then 
move on to assay salivary samples using the same 
protocol. However, there are drawbacks to this 
approach. A serum IgA response cannot be induced 
without stimulating the production of other 
immunoglobulin isotypes, particulary IgG, which is much 
more abundant in the serum than IgA. Therefore, in the 
serum, there are many anti-OVA antibodies, but only a 
small proportion of these are IgA. So in the ELISA, the 
anti-IgA conjugate has relatively few sites with which 
to combine specifically. Lack of specificity of this 
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reagent will result in binding to other more abundant 
isotypes and will lead to false positive results. 
Therefore, the research was very dependent on the 
quality of one reagent, which is produced biologically, 
and whose quality cannot be assessed. However, the 
supplier's literature states that the conjugates are 
"specific for the respective rat immunoglobulin 
proteins when tested by immunodiffusion and 
immunoelectrophoresis against a variety of rat sera and 
other immunoglobulins". Although, of course, it would 
be more satisfactory if the reagents were affinity 
purified, but none was available. 
Serum IgA may not necessarily have identical binding 
properties to salivary IgA, since secretory component 
and other factors in secretions may interfere with 
antigen-antibody interactions. However, since IgA is 
not available commercially, no assessment can be made 
of the possible inhibitory effects of salivary 
components. Whilst recognising the drawbacks of this 
approach, the ELISA was validated by a demonstration of 
its ability to determine rat antibodies in serum, both 
IgA and IgG, following i.p. injection of the model 
protein. The detection of antibodies in the saliva 
proved to be a problem. Several immunisation protocols 
proved ineffective at inducing a salivary response. A 
response to myoglobin was eventually induced only when 
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it was administered orally on four consecutive days, 
followed by a 'booster' oral dqse, more than two months 
later. Ovalbumin, administered at a higher dose, 
induced a significant salivary response after oral 
administration over four consecutive days only. 
However, subsequent data did bring into question the 
interpretation of these results as 'significantly 
positive' as the response was compared with the 
salivary response from only two "blank" animals. This 
limitation in experimental design is explained by our 
reluctance to use a large number of experimental 
animals at this early stage. We were unsure about the 
effectiveness of this immunisation protocol, but needed 
to demonstrate that at least a small salivary response 
would be induced, so that we could then move onto the 
next stage of the work and try and enhance this. The 
response induced seemed to justify moving onto the next 
stage, the oral intubation of OVA associated with the 
chosen colloidal carriers. 
The simple and accurate technique of Lowry proved 
applicable to the quantitative determination of 
proteins incorporated into or adsorbed onto liposomes 
and p(BCA) particles respectively. The adsorbed protein 
could not be recovered from p(BCA) particles, so the 
amount left in the supernatant after collection of the 
particles was assayed and the value subtracted from 
-204-
that added initially. The entrapment of protein in 
polyacrylamide microparticles was determined by HPLC 
after hydrolysis and derivatization of the constituent 
amino acids. 
Oral administration of ovalbumin incorporated into 
DSPC/CHOL liposomes led to slightly enhanced immune 
responses, both in the serum and the saliva. But the 
enhancement was not statistically significant. However, 
since both IgA and IgG responses were enhanced in both 
serum and saliva, it seems less likely that these 
values could have arisen purely by chance. The results 
raise the possibility that, perhaps with a different 
immunisation protocol, or for a different antigen, 
DSPC/CHOL liposomes may prove an effective oral 
adjuvant. However, the recently reported lability of 
DSPC/CHOL liposomes in simulated intestinal media and 
the reported lack of absorption of entrapped markers by 
intestinal cells (166) may belie this note of optimism. 
The volume of saliva collected from the liposomal 
experimental animals was recorded, to ascertain if this 
would greatly affect the ELISA result. The volume 
collected from each animal varied from 300-500pl (mean 
388 ±55pl), but since the ELISA values varied so 
little, these values were of no consequence. It was 
concluded that the immunisation protocol used was 
innappropriate to the induction of a significantly 
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positive salivary immune response. Which indicated that 
we had not elicited a significant positive salivary 
antibody response when this immunisation protocol had 
been used previously in chapter 3. As explained, this 
response had been compared with only two 'blank' 
samples at the time. This work could have been 
repeated, with more 'blank' samples, but instead the 
immunisation protocol was expanded for subsequent 
experiments to also include an oral priming dose of 
OVA. Therefore, in the subsequent experiment, involving 
polyacrylamide microparticles, which appeared to have 
greater potential as an oral adjuvant, an oral priming 
dose of ovalbumin was administered. 
Initially, two experiments with polyacrylamide 
microparticles were performed, PAl and PA2: with PA2 
being a continuation of PAl designed to show the effect 
of a booster dose of antigen administered orally, in 
particulate and soluble form, two weeks after the 
commencement of the repeated oral administration. 
Unfortunately, the results from PAl and PA2 were very 
disappointing, no significantly positive responses were 
seen in the serum or the saliva of any group of 
animals. A radioimmunoassay, proven to be capable of 
detecting both IgG and IgA rat anti-OVA antibodies, 
indicated that the negative results were not due to 
lack of sensitivity of the ELISA. Therefore, it was 
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concluded that the immunisation protocols for PAl and 
PA2 were poorly designed, despite being based on 
literature reports and our own previous results. 
In experiment PA3, an intraperitoneal priming dose 
was administered to the animals and, since the 
necessary licence had been obtained from the Home 
Office, sequential sampling was performed, to allow us 
to assess fully any changes in the immune responses. 
The time course of this experiment was extended so that 
the 'memory' response to oral administration of antigen 
more than two months after the initial intubation could 
be assessed. In previous work, the memory response was 
considerably larger than the primary response. Six 
capillary tubes of saliva was collected from each 
animal at each collection point, which constituted a 
total of over 200pl. 
After 14 days, the group mean salivary responses did 
not differ and were not raised above the 
pre-inoculation levels. However, the mean serum IgG 
response for both the particulate and the control group 
was raised, as was the control group serum IgA 
response. But the large degree of variation within the 
groups meant that the control and the particulate group 
responses were not raised significantly above the blank 
group value. This degree of variation within groups is 
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common when biological responses are assessed from a 
number of unrelated individuals. 
The mean memory salivary IgA response of the 
particulate was significantly raised ( p<O.Ol in 
Unpaired Student "t" test) relative to the control 
group and there was much less inherent variation in the 
group values than was seen for the serum response. This 
result raises the possibility of inducing enhanced and 
more reliable salivary immune responses on re-exposure 
to antigen, if the antigen is administered initially as 
a particulate. The persistent presence of the antigen 
in the tissues, in an immobilised form, after uptake 
via the PP was postulated as an explanation for the 
enhanced salivary response. 
Both control and microparticulate group mean serum 
IgG responses remained higher than the blank for the 
memory response, but again, there was large variation 
within the groups. 
It can be concluded from these data that the oral 
administration of ovalbumin incorporated in 
polyacrylamide microparticles can lead to an enhanced 
secretory immune response, depending on the 
immunisation protocol used. Other microparticles, which 
either confer protection against the degradative 
properties of the gut on an entrapped antigen, and/or 
promote uptake by PP, might be expected to display a 
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similiar adjuvanticity. More biodegradable and 
biocompatible systems seem appropriate for further 
studies, although, the non-biodegradability of 
polyacrylamide microparticles may be of paramount 
importance to the oral adjuvanticity. 
The immunisation protocol used in PA3, was repeated 
for a further experiment involving p(BCA) particles 
with adsorbed ovalbumin. Two groups of animals were 
given particles, which differed only in particle size, 
due to the different stabilising agents used in their 
preparation. It was demonstrated that ovalbumin was 
efficiently adsorbed to the particles (70-80% at 4mg/ml 
ovalbumin) in vitro, and that the adsorption was 
reproducible. However, it cannot be predicted how much 
ovalbumin would remain adsorbed to the particles in 
vivo, after oral administration. There is likely to be 
competitive displacement of ovalbumin at the particle 
~ u u
surface d u e ~ t h e e adsorption of proteins and other 
materials present in the gut, analogous to the 
adsorption of blood components onto non-biological 
interfaces when combined (210). 
The 14 day sera IgG response in the group 
administered OVA adsorbed to poly 2-butylcyanoacrylate 
particles stabilised by dextran was 
significantly raised relative to the control group 
response (significant at p <0.001 in Unpaired Student 
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"t" test). Although the mean ELISA value for the group 
administeredcyclodextrinstabilised particles was 
greater than the value obtained for the aforementioned 
particle group, the large amount of variation in the 
response meant that the sera response was not 
significantly raised above the control group response. 
These results raise the possibility of inducing better 
sera immune responses to an orally administered 
antigen, if the antigen is adsorbed to a particulate 
carrier. It seems a more reliable response is obtained 
if the carrier has a size of a b o u t l ~ O n m m as opposed to 
: 3 ~ m m • 
The 14 day saliva IgA response was raised 
significantly relative to the control groups for both 
groups administered OVA adsorbed to particles, beta 
cyclodextrin and dextran 70 stabilised (significant at 
p <0.01 and p <0.02 respectively in Unpaired Student 
"t" test). The saliva IgA memory response for the group 
administered dextran stabilised particles was 
significantly raised above the control group response 
(significant at p <0.05 in Unpaired Student "t" test). 
These results raise the possibility of inducing better 
secretory immune responses to orally administered 
antigens if the antigens are adsorbed to particulate 
carriers. Better memory responses in the secretory 
tissue may also be elicited with a particulate carrier. 
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It was thought that the enhanced immune responses 
after 14 days are a consequence of both the degradation 
of the particles after uptake into the PP, which will 
cause release of adsorbed OVA, and also desorption of 
OVA from intact particle. Both of these will result in 
the release of OVA over a quite short time period and 
so are likely to result in an enhanced short term 
immune response. The better saliva IgA memory response 
from the group administered dextran 
stabilised particles is likely to be a consequence of 
particle size. The small particle size, compared to 
cyclodextrin stabilised particles, or possibly the 
dextran component, may make the particles more 
difficult to degrade in vivo eg. uptake by macrophages 
etc. may be less efficient. 
The results from chapters 5 and 6 indicate that 
particulate carriers can gain access to the PP tissue 
after oral administration and can result in enhanced 
immune responses to an incorporated, or adsorbed 
antigen. But there was no direct evidence to show the 
uptake of these carriers after oral administration. The 
next part of this work was undertaken to rectify this. 
The electron microscopy study was undertaken 
ostensibly to indicate that p(BCA) particles are a 
suitable candidate for oral immunisation studies by 
virtue of their in situ uptake into M-ce11s. But the 
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gold labelled particles were not suft1ciently electron 
dense to allow their visualization in the tissue 
sections. However, it was possible to identify putative 
M-cells in the epithelium overlying the PP, despite the 
colloidal particles themselves not being visible. 
The fundamental problem encountered in this research 
work, was the unreliable and non-reproduceable nature 
of the salivary immune response. In part, this may be 
explained by interference of antigen-antibody reactions 
in the ELISA by salivary components, by loss of 
antibody activity on freezing and thawing, by batch to 
batch variation in the quality of the anti-rat IgA 
conjugate, or perhaps low reactivity of this reagent 
with salivary IgA. However, although the 'common 
mucosal immune system' was conceived to include 
salivary and mammary glands (137), subsequent evidence 
showed that intestinal lymphoblasts are primarily 
tissue-specific and hence migrate to these other 
. 
mucosal sites in much smaller numbers (21+>. This 
perhaps offers a better explanation of the poor 
salivary immune response to gastrically administered 
antigens, but does not invalidate the measurement of 
the secretory immune response from the saliva. However, 
a direct determination of the intestinal antibody 
response would be preferred if possible. 
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Overall, we feel that this work offers encouragement 
towards the further investigation of the potential of 
microparticulate systems as orally administered 
immunological adjuvants. 
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9. Future work. 
Standard methods for protecting antigens against 
degradation in the gut ego enteric coating, or 
concomitant administration of sodium bicarbonate, will 
not be discussed here, since these methods are well 
established and have been employed in large scale 
clinical trials in man for oral immunisation against 
typhoid fever (215,216). 
As an aid to the design of peroral vaccines based on 
polymeric particles, a more fundamental understanding 
of the factors governing the uptake and transport of 
particulates by the PP would be of great benefit. It is 
felt that a detailed study should be undertaken, with a 
wide range of particles of known size, surface charge, 
hydrophobicity etc. to determine exactly which surface 
properties render the particles more attractive for 
uptake by M-cells. However, although characterisation 
of the surface properties governing uptake would be of 
great benefit, the effects of adsorbed or incorporated 
antigen and the effects of material adsorbed to the 
particles in the gut must also be considered. To allow 
their visualization in the electron microscope, the 
particles must first be labelled to render them 
sufficiently electron dense, ferritin offers promise as 
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an effective label which has been shown to be taken up 
by PP. 
The quantification of the uptake of particles into 
the PP may prove difficult, but labelling particles 
with radioisotopes and subsequent counting of activity 
in excised PP tissue could solve this problem. The fate 
of particles in subjacent tissues could also be 
followed using microautoradiographic techniques. The 
processing of particulates by dendritic cells, 
macrophages and lymphocytes may be dependent on 
characteristics such as size, surface charge, 
hydrophobicity etc. The induction of a positive 
secretory immune response will depend on the effective 
processing of antigens by these cells and 
microautoradiographic studies may help to clarify this 
complex intracellular and intercellular processing. 
Much may be learnt about the uptake and transport of 
materials by M-cells by the study of the uptake and 
transport of bacteria and viruses. The bacterium Vibrio 
cholerae is taken up and transported by M-cells (97,99) 
and the process must be active, since the organism is 
non-invasive. Chlamydia have been observed in the 
M-cells of calves with diarrhoea, but transport in PP 
has yet to be demonstrated (217). More interestingly, 
certain organisms, such as RDEC-l Escherichia coli and 
Reovirus type 1, seem to bind preferentially to M-cells 
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(95,99,105). RDEC-l attaches to M-cells long before it 
manifests general colonization of the mucosal surface 
(105). Adherence was found to be dependent on a plasmid 
encoded pilus, which suggests that M-cell binding is at 
least part dependent on the presence of certain M-cell 
specific surface molecules (218). Reovirus binding to 
absorptive cells is dependent on a surface protein 
different to the one responsible for binding to M-cells 
(96). These observations raise the possibility of 
M-cell binding factors, which, if successfully 
identified and isolated may provide a specific 
mechanism for targetting to M-cells. The RDEC-l E.coli 
strain, may be grown in media to promote pilus 
production, the pilus may then be isolated and linked 
directly to an antigen, or possibly linked onto the 
surface of a colloidal carrier incorporating the 
antigen. 
Differences in M-cell apical membrane may also offer 
possibilities for targeting (107-9). The ability of 
M-cells to act as an entry route for the uptake of 
materials into the PP, will depend not only on the 
binding characteristics of the cell, but also on the 
ability to endocytose material. Two strains of E.coli 
which have the same ability to bind to M-cells, differ 
in their capacity to be transported into the lymphoid 
follicle (219). 
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Concerning the non-reliability and 
non-reproduceability of the salivary IgA response, in 
future experiments, the small intestine, from the 
duodenum to the ileocaecal junction, could be removed, 
homogenised and the intestinal antibody isolated. This 
method would allow a direct determination of the gut 
immune response, which would be of particular 
importance when immunising against intestinal 
pathogens. Furthermore we could still assess the on 
going immune response by sequential salivary 
collection. An assessment of the cellular immune 
response could be performed by a lymphocyte 
proliferation assay in the presence of the immunising 
antigen, after collection of mesenteric lymph and 
isolation of the lymphocytes. 
We considered that future work should be directly 
concerned with the causative agents of enteric, and 
possibly other mucosal-site, infections and not with 
model antigens. It should be remembered that, since 
lymphocytes seed out to other mucosal sites after oral 
administration, peroral vaccination may also elicit 
protection against respiratory pathogens such as 
Haemophilus influenzae and Bordetella pertussis or 
uro-genital pathogens such as Neisseria gonorrhea. 
Studies with cholera have revealed the important 
principle of synergism between antigens interfering 
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with different pathogenic events such as colonization 
and toxin action (220). This principle has been amply 
supported for the action of anti-CFA (colonization 
factor antigens) and anti-LT (heat labile enterotoxin) 
antibodies in protection against experimental 
enterotoxigenic E.coli infections (221). Therefore, 
future work in the development of enteric vaccines 
should be aimed towards the establishment of 
synergistic cooperation. 
Again, it seems that much can be learnt by the study 
of the mode of action of microbiological agents. 
Cholera toxin is an excellent mucosal immunogen, 
probably both due to its ability to bind to cell 
membrane GM1 ganglioside receptors, which may be 
present on M-cells and its ability to activate 
adenylate cyclase in lymphoid tissue. Cholera toxin has 
the ability to markedly enhance the response to 
unrelated antigens (222). In fact, two synthetic 
peptides of only 20 and 25 amino acids respectively, 
corresponding to peptide sequences in the cholera toxin 
B chain, have been shown to be effective adjuvants when 
given orally or intraperitoneally (223). These 
particular sequences were chosen because of their 
predicted surface localization. Perhaps the most 
efficient way of inducing a mucosal immune response 
will prove to be through linking of synthetic peptide 
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sequences, like those from cholera toxin, with the 
proposed antigen, incorporated into a protective 
colloidal carrier. Cholera toxin is proposed to work in 
vivo by providing extra help in the induction of 
precursor B cells in PP by mimicking or replacing the 
action of T helper cells and at the same time 
inhibiting the induction and lor function of T 
suppressor cells. An appropriate colloidal carrier 
would be chosen to ensure that the cholera toxin gains 
effective access to the PP. 
There are several, perhaps less feasible approaches 
to enhancing immune resonses to orally administered 
antigens. Firstly, linking antigens to soluble, cross 
linked N-(2-hydroxypropyl) methacrylamide copolymers. 
These polymers have been shown to be pinocytosed by rat 
intestine in vitro, with the rate of uptake increasing 
with increasing size of the polymer (224). Secondly, 
encouraging the lymphatic absorption of antigens eg. by 
their attachment to high molecular weight dextran 
carriers (225). Certain large molecular weight toxins, 
such as botulism toxin, have been found in significant 
levels in the lymph (47). Thirdly, a greater 
understanding of receptor mediated and facilitated 
transport mechanisms dealing with dietary materials eg. 
receptor mediated endocytosis of vitamin B12 (53-56), 
may offer possibilities for the enhanced uptake of 
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suitably tailored molecules. Fourthly, another 
possibility may be to produce particles directly from 
antigens. Insulin nanoparticles were reportedly active 
after oral administration (39) and particles may be 
prepared by the coacervation of many macromolecules 
(226). Although all of these approaches have serious 
limitations, in some situations they may prove 
applicable and are worthy of consideration. 
This thesis has dealt only with the potential of 
pharmaceutical formulations as oral adjuvants, there is 
undoubtably great scope for further research into the 
potential of pharmaceutical formulations as adjuvants 
for other modes of administration. A recent review 
paper by Allison (227) shows the rational development 
of a very promising injectable adjuvant formulation, 
developed following sound pharmaceutical reasoning. 
Perhaps this will prove to be the first of many such 
developed vaccines. There is no indication that this 
adjuvant is effective orally. 
It has been suggested that the human 
immunodeficiency virus (HIV) gains access to the body 
via the M-cells in the lymphoid follicle rich rectum 
(228). If this is so, then possibly oral immunisation 
with a killed, or inactivated portion of the virus in 
an effective adjuvant may provide the first line of 
defence against this highly dangerous pathogen. 
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